I. National Key Programs

1. Surgery (General Surgery)

2. Internal Medicine (Cardiovascular disease)

 

3. Occupational and Environmental Health

4. Pathology and Pathophysiology

5. Obstetrics and Gynecology

 

6. Internal Medicine (Respiratory disease)

 

 

 

7. Surgery (Urinary Surgery)

  

8. Internal Medicine (Hematological Disease)

 

9. Anesthesiology



 

II. Academic Teams:

Prof. CHEN Jianguo’s Team

----Neuropsychiatric Pharmacology

 

A. Introduction of the Team

This academic team is composed of senior professors and experts from the School of Basic Medicine and the School of Pharmacy in Tongji Medical College (TMC) of Huazhong University of Science & Technology (HUST), most of them are specialized in Neuropsychiatric Pharmacology, committed to explore the pathogenesis of nervous diseases and the intervention strategy based on synaptic plasticity and ion channel. The team boasts notable advantages in depression and drug addiction research.

Team Leader: Prof. CHEN Jianguo

Prof. CHEN Jianguo acquired his master degree in former Tongji Medical University in 1990, then pursued his academic career as a visiting scholar at the University of Kaiserslautern in Germany from Nov. 1995 to Sept. 1996. In the following two years, he transferred to Heidelberg University and got his doctor degree there and did postdoctoral research program under Dr. Toshinori Hoshi at the University of Iowa in USA. Since 2002, he returned to China and worked at Tongji Medical College and later became the Chairman of the Department of Pharmacology and now he is the Dean of TMC and Vice-President of HUST.

In 2004 he was awarded as Distinguished Young Scientist by the National Natural Science Foundation of China (NSFC); in 2007 he was endowed Distinguished Professor of Yangtze Program by Ministry of Education of China; in 2013 he was appointed to be the Chief Scientist by the National Basic Research Program of China (973 Program).

Team Members:

Prof. WANG Jianzhi, M.D., a prominent professor with outstanding accomplishment in neurology, pathophysiology and bio-neuropathology, Director of Pathophysiology Key Laboratory of Chinese Ministry of Education, focusing on Alzheimer disease including pathogenesis, early diagnosis and prevention; also interested in emotion and learning memory, neurodevelopment and neural circuitry. She was selected by the National Ten Thousand Talents Project, and awarded as Creative Team Leader for Neurological Disorders,  National Model Teacher for Education, National Prestigious Teacher Award for Teaching, Changjiang Distinguished Professor of Ministry of Education of China etc.

Prof. ZHANG Yonghui, Ph.D, Changjiang Scholars, full professor specialized in pharmaceutics, Dean of TMC School of Pharmacy; serves as inter-discipline bridge between pharmacology and pharmaceutics in the team. Major research interests focus on Natural Medicinal Chemistry and Innovative Drugs Development.

 

Prof. Dr. WANG Fang, Ph.D in Pharmacology, full professor, research interests focus on neuropsychopharmacology, depressive disorders and drug addiction. Contact: http://english.tjmu.edu.cn/info/1027/1050.htm

Prof. LONG Lihong Ph.D in Pharmacology, full professor, chief member of the team, research interests focus on energy metabolism, mitochondria dysfunction, neuropsychological disease. Contact and detailed information: http://english.tjmu.edu.cn/info/1027/1132.htm

Prof. HU Zhuangli, Ph.D in Pharmacology, full professor, research interests focus on  ion channel; glial cells; mental disorder. Detialed information: http://english.tjmu.edu.cn/info/1028/1539.htm

Prof. WU Pengfei, Ph.D in Pharmacology, associate professor of TMC, research interests focus on neuropsychopharmacology, redox biology and translational medicine. Detailed information: http://english.tjmu.edu.cn/info/1028/1099.htm

窗体底端

B. Main Research Areas

Neuropsychiatric pharmacology; ion channel and synaptic plasticity associated with cognitive and emotional disorders, the pathogenesis of above disorders; pharmaceutic intervention on the depression and drug addiction

C. Background & Significance

Depression is one of the most common neurological disorder which seriously affects the living quality of the patients and their folks. It’s predicted by WHO that depression will become one of the most fatal diseases by 2020, second to carcinoma. Drug addictions (such as cocaine, heroin and methamphetamine addiction) also induce serious social and public health hazards, with remarkable significance in our research on pharmaceutic intervention.

D. Achievement & Awards

The team has published 90+ papers in world-renowned SCI journals like Nature, Neuron, Nat Neurosci, Mol Psychiatry etc. with more than 2,900 times citations. Prof. CHEN Jianguo and his team members have been taking in charge of different scientific research projects at national or ministerial level, such as the Key Projects of Chinese National Science Fund (NSFC), “973 Program”, Medical Projects of NSFC for Distinguished Young Scholars, etc. The recent ongoing projects include: NSFC National Innovation Research Group Project 81721005 titled Neuropsychiatric Medications, 2018/01-2023/12, 10,5 million and NSFC General Program 81673414 titled The Role and Mechanism of Caspase-1 Mediated AMPA Receptor Shear and Dysfunction in Cocaine Addiction; 2017/01-2020/120.5 million.

As the Dean of Tongji Medical College and the Vice-President of HUST, Prof. Dr. Chen has remarkable reputation for his outstanding contribution to teaching and research in the medical field. Moreover, 2 of his team members were awarded the Prizes for Young Pharmacologists by Chinese Pharmacological Society.

 


Prof. LU Youming’s Team

----Neuroscience & Brain Diseases

 

A. Introduction of the Team

Team Leader: Prof. Dr. Lu Youming, dean of the TMC School of Basic Medicine and director of Brain Research Center of HUST, acquired his Ph.D in neuroscience at the University of Toronto in 1998. After postdoctoral training at Columbia University, he was appointed to tenure-track assistant professor at University of Calgary, Canada,     followed by an endowed tenure full professor at Health Science Center, School of Medicine of Louisiana State University in 2008. Research interests focus on neuronal signaling processing and circuits in learning and memory, as well as major neurological disorders. He has received several major funds, including the National Natural Science Foundation Innovation Research Group and 4 major research projects from NSFC (Natural Science Foundation of China). He was awarded as Thousand Talents Program Professor and National Distinguished Experts in 2011.

Team Members:

Prof. Dr. ZHU Lingqiang, specialist in pathophysiology, scientist of 10,000 Talents Plan, winner of New Century Excellent Talents Program in Ministry of Education, in charge of science and technology innovation and entrepreneurship talent project and Joint platform for molecular biology of neuropathy between HUST and Toronto University, senior editor of Journal of Alzheimer’s Disease. His research focuses on prevention and treatment at early age of Alzheimer’s Disease and coordinated several projects funded by Natural Science Foundation of China.

Prof. Dr. TIAN Qing, female, member of New Century Excellent Talents Project conducted by the Chinese Ministry of Education, research interests focus on the mechanism of cerebrovascular reconstruction, endoplasmic reticulum/golgi body stress with Neuronal injury. She has been in charge of several national natural science fundings and has published 20+ SCI research papers.

Prof. Dr. LIU Dan, female, Ph.D in pathophysiology, assistant professor, research interests focus on mechanism of synaptic diseases and neurogenesis of Alzheimer’s Disease. She has published 13 SCI research papers, including some authoritative journals such as Neuron, Biological Psychiatry, Molecular Psychiatry.

Prof. Dr. PEI Lei, Ph.D in neurobiology, 2-year visiting scholar at Dutch Royal Science Academy, focusing on the neurologic mechanism of neurological diseases, mainly in chronic pain and ischemia, in charge of several national and international fundings and published 13 SCI research paper and a reviewer of Frontiers in Molecular Neuroscience.

Dr. ZHU Houze, Ph.D in pathophysiology, lecturer, 8 SCI papers published as first author.

B. Main Research Areas

1. the cellular and molecular mechanisms underlying learning and memory. The major research interests are neuronal signaling processing and circuit that underlies learning memory.

2. Alzheimer’s Disease and its early symptom as memory loss on diverse research level including micro-RNA, proteomics and molecular signal pathways.

C. Background & Significance

With the development of single synaptic neuronal tracing and molecular imaging technology, scientists had begun to recognize that some neuronal circuit can be regulated for specific brain function. Single synaptic neuronal tracing could be used in a same species of neuron which has the same bio marker and shed light on the detail projection from those neurons or to those neurons. Combined with optogenetic technology, scientists will clarify the function of these neuronal circuits in the brain. However, neurons with unambiguous bio marker are a very small fraction compared to neurons in whole brain. The vast majority neurons are lack of specific bio marker based on the current knowledge. Structures and functions of neuronal circuit composed via those neurons still keeps unknown. Searching for the specific bio marker for those neurons and determining their functional circuits is a frontier question for life science.

At the same time, discovery of the brain’s advanced function and activities (storage of learning memory, formation of consciousness etc.) are the most advanced natural scientific questions in 21th century defined by the most influenced natural scientific magazine Nature. Therefore, finding specific bio markers for those “unidentified” neuron and determination of their specific neuronal circuit is not only important to uncover the cognition of whole brain neuronal circuit but also form a theoretical basis for treatment of human illness associated with memory loss, such as Alzheimer’s Disease Academic Strength (Talents, Laboratory Facilities & Equipment, Sample Size, Regional Coverage etc.)

D. Resources & Advantages

This team has an international-leading platform. Apart from the whole composition in traditional biochemistry lab, cell culture lab, behavior lab, and in vitro electrophysiology lab, optogenetic lab, it possesses some novel and precise instruments, namely 3 confocal microscopes (one for in vitro electrophysiology), cell soring and analytical flow cytometer, live cell workstation, digital imaging microscope, high resolution field microscope, Skinner’s behavior system etc.

E. Achievements & Publications

Since the establishment, this team has already obtained 20 national or international projects with sufficient funding, and published 100+ SCI research papers, including authoritative science journals as Neuron, Molecular Psychiatry, Nature Communications, Biological Psychiatry, Cerebral Cortex etc. It also developed undergraduate courses and textbooks, sponsored 3 international conferences on neurological disease and brain networks in 2012, 2014 and 2016.

 

 


Prof. WANG Jianzhi’s Team

----Alzheimer’s Disease

 

A. Team Introduction

Academic leader:     Prof. Dr. WANG Jianzhi, prominent professor with outstanding accomplishment in Neurology, pathophysiology and bio-neuropathology, Director of Pathophysiology Key Laboratory of Chinese Ministry of Education, focusing on Alzheimer’s disease including pathogenesis, early diagnosis and prevention; also interested in emotion and learning memory, neurodevelopment and neural circuitry. She was selected by the National Ten Thousand Talents Plan, and awarded as Creative Team Leader for Neurological Disorders, National Model Teacher for Education, National Prestigious Teacher Award for Teaching, Changjiang Distinguished Professor of Ministry of Education of China etc.

Team Members:

B. Key Research Direction

Pathogenesis of Alzheimer’s Disease(AD) and its early diagnostic strategy

C. Background and Significance

Alzheimer Disease is the most common, age-related disease characterized by progressive neurodegeneration. The incidence of AD has dramatically increased in association with aggravating aging population. However, AD remains a mystery with no early, high specific, high sensitive diagnostic indicators, and without effective prevention and treatment, which imposes a serous threat to people’s health and a hazard to today’s society and families.

This team is committed to researching the pathogenesis of Alzheimer Disease (AD) and its early diagnosis strategy. The team has achieved a series of innovations on revealing the role of tau in Alzheimer-like neurofibrillary degeneration and monitoring technology with an extensive international influence. The team has published 207 SCI papers, more than 200 papers in Neuron, Nat Commun, Prog Neurobiol, PNAS, J Neurosci and so on, among which have been cited over 6000 times by SCI. The team researchings have won one second prize of the National Natural Science Award and four first prize of Provincial or Ministerial Natural Science Awards. Under the leadership of Prof. WANG Jianzhi, the team took in charge of several major research projects, such as Projects of International Cooperation and Exchanges NSFC, the Key Projects of Major Research Plan, International Science and Technology Cooperation Program of China, the Major Research plan of China, the General Program of NSFC and so on.

D. Research Achievements, Awards, Publications

Scientific and Technological Achievements Awards

1. Molecular Mechanisms Underlie Alzheimer-like Tau Hyperphosphorylation and Neurodegeneration; Second Prize of the National Natural Science Award; Year 2010; Certificate No :2010-Z-106-2-01-R01

2. Mechanisms of Tau Hyperphosphorylation and Its Effect on the Survival of Neurons; First Prize of Higher Institution’s Natural Science Award; Year 2009; Certificate No :2008-029

3. Effect and Clinical Significance of Abnormal Cytoskeleton Proteins in Pathogenesis of AD; First Prize of National Science and Technology Award Nominated by the Ministry of Education; Year 2005; Certificate No :2004-028

4. Effect and Potential Value of GSK-3 in Alzheimer-like Tau HyperphosphorylationFirst Prize of Hubei Provincial Natural Science Award; Year 2008; Certificate No :2008Z-028-1-006-004-R01

5. Abnormal Modification of Cytoskeletal Proteins and Its Mechanism in Alzheimer Disease; First-Class Prize of Chinese Medical Science and Technology Award; Year 2002; Certificate No :200201050P0501

Research Patents

1. Name: Neurotrophic factor fusion peptide of brain targeting for resisting Alzheimer; Disease and its Preparation Method; Approval year: 2012; Patent noZL201010210143.7

2. Name: Fusion Polypeptide crossing the blood-brain barrier to resist Alzheimer Disease; Approval year: 2012; Patent noZL201010182630.7

 

 

 



Prof. HU Qinghua’s Team

---- Respiratory Disease

 

  1. Introduction of the Team

    This academic team is composed of senior professors and professionals from the School of Basic Medicine, Tongji Hospital and Union Hospital of Huazhong University of Science & Technology (HUST). Most of them are experts in respiratory pathophysiology and the clinical medicine. The team boasts notable advantages in pulmonary hypertension, heart failure, chronic obstructive pulmonary disease, and asthma.

    Academic Leader: Prof. HU Qinghua

    Dr. Hu is a Professor of Medicine and Physiology and Deputy Director of Key Laboratory of Pulmonary Diseases of Ministry of Health. He earned a Medical Doctoral Degree in 1989 and a Doctorate of Philosophy in Physiology in 1994 from Tongji Medical University He received his post-doctoral training in endothelial biology at Johns Hopkins University School of Medicine, and joined the faculty as Instructor and Assistant Professor (tenure-track) at Johns Hopkins (1996-2006). He then returned to Tongji Medical College, Huazhong University of Science and Technology as a Professor and became the vice-director of Key Laboratory of Pulmonary Diseases of Ministry of Health.

    Team Members:

    Prof. WEI Xiang, M.D., Ph.D. Professor, Department of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. His research interests focus on cardiac remodeling and pulmonary hypertension.

    Prof. ZHEN Guohua, M.D., Ph.D. Professor, Department of Respiratory and Critical Care Medicine, Tongji Medical College, Huazhong University of Science and Technology. His research interests focus on the pathogenesis of chronic obstructive pulmonary disease and clinical treatment.

    Prof. XIONG Weining, M.D., Ph.D. Professor, Department of Respiratory and Critical Care Medicine, Tongji Medical College, Huazhong University of Science and Technology. His research interests focus on the pathogenesis of asthma and airway inflammation disease and clinical treatment.

    Prof. ZHU Liping, M.D., Ph.D. Associate professor, Department of Pathophysiology, Tongji Medical College, Huazhong University of Science and Technology. Major research interests focus on the calcium-kinetics encoding downstream events and pathogenesis of pulmonary hypertension.

    Prof. LI Jiansha, M.D., Ph.D. Associate professor, Department of pathology, Tongji Medical College, Huazhong University of Science and Technology. Major research interests focus on pathology and pathogenesis of lung cancer.

    Prof. SU Yuan, M.D., Ph.D, Departments of Respiratory Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Major research interests focus on pathogenesis of pulmonary hypertension and airway inflammation disease and clinical treatment.

     

  2. Main Research Areas

    The pathogenesis of pulmonary hypertension, chronic obstructive pulmonary disease, asthma, and right heart dysfunction and calcium kinetics-encoded cellular events.

  3. Background & Significance

    This research team works on the pathogenic mechanisms of pulmonary hypertension, asthma, and COPD as well as calcium kinetics-encoded cellular events employing up-to-date technology. Since releasing the first exploration on the extracellular calcium-sensing receptor (CaSR) in triggering hypoxic pulmonary vasoconstriction and pulmonary hypertension, the laboratory has identified CaSR as the molecular target of monocrotaline-induced pulmonary hypertension, and HIMF as a non-classical ligand of CaSR in the development of hypoxic pulmonary hypertension. The laboratory recently revealed the role of cumulated spike duration in encoding irregular calcium oscillations-stimulated transcription. They continue to investigate in-depth mechanisms underlying the development of pulmonary hypertension. This team receives continuous support from the National Natural Science Foundation of China (NSFC) and the Ministry of Science and Technology of China.

  4. Achievement & Awards

    This research team has published more than 60 papers in prestigious SCI journals, including Lancet, Nat Commun, Circulation, Circ Res, Am J Respir Crit Care Med, Proc Natl Acad Sci USA, Hypertension, J Cell Sci, J Biol Chem, Am J Physiol, etc. Prof. HU Qinghua and his team members have being awarded more than 11 national research grants totalling more than 12 million, including the Key Project from National Science Foundation of China (NSFC), National Key Research and Development Program from Ministry of Science and Technology of China.


Prof. WU Tangchun’s Team

---- Environment-Related Diseases

 

A. Introduction of the Team

Team Leader: Prof. Dr. WU Tangchun, Ph.D, Dean of the School of Public Health, a full Professor specialized in Environmental and Occupational, Director of Key Lab for Environment and Health funded by Ministry of Education and Ministry of Health, visiting scientist of Lab. of Molecular Genetics (National Key Lab) in Huazhong Agriculture University (Wuhan). Prof. WU pursued his post-doctoral research and was visiting professor at the Lab. of Molecular and Development Genetics in Laval University, Canada.

窗体底端

Team Members:

Prof. CHEN Weihong, Ph.D in University of Essen in German, a prominent professor of the School of Public Health in TMC and adjunct professor of the Chinese University of Hong Kong, specialized in Occupational and Environmental Health, research interests focus on health effects and pathogenesis (on human) of particulate matter exposure, especially respiratory diseases. In her long-year research and teaching, she has published enormously and won numerous funding projects in related areas. More detailed information see: http://english.tjmu.edu.cn/info/1076/1166.htm

Prof. PAN An, Ph.D in the Institute for Nutritional Sciences in Chinese Academy of Sciences, Shanghai, Professor of Epidemiology and Assistant Dean in the School of Public Health, research interests focus on non-communicable diseases, such as obesity, metabolic syndrome, and type 2 diabetes. Prof. PAN was a researcher in Department of Nutrition in Harvard School of Public Health, and Assistant Professor in Saw Swee Hock School of Public Health, National University of Singapore, Singapore; he won many international prizes and has been the chief editor of many renowned journals in the field of Epidemiology. Detailed information: http://english.tjmu.edu.cn/info/1076/1210.htm

Prof. HE Mei’an, Ph.D, a full professor in the School of Public Health, TMC of HUST, academic areas specialized in Occupational and Environmental Health. Detailed information: http://english.tjmu.edu.cn/info/1076/1176.htm

The other two members includes Dr. ZhangXiaomin and Dr. GUO Hua

B. Main Research Areas

The Prevention and etiology of major environment-related disease academic team concentrated on the etiology and prevention of major environment-related diseases including cardiovascular disease, diabetes, cancer and respiratory disease.

1. Biological significance of heat shock proteins and their related proteins in the stresses or diseases with the techniques of molecular and cellular biology, toxicology, epidemiology and others. 2. Carcinogenesis and biomarkers of occupational and environmental related lung cancer and coronary heart diseases. 3. Occupational, environmental exposures and coronary heart diseases in cohort. 4. Environments, genes and their interaction on the cardiopulmonary injury and diseases.

C. Background & Significance

This academic team established the Dongfeng-Tongji cohort in 2008 and finished the first follow-up in 2013. This cohort included 27,009 retirees from Dongfeng Motor Corporation at baseline. In 2013, we enrolled 38,295 individuals and the follow-up rate is 96.2%. Based on this cohort, we investigated the etiology and prevention of major environment-related diseases including cardiovascular disease, diabetes, cancer and respiratory diseases. Also, we collaborated with other cohorts such as CKB, NHS, HPFS, and so on. This academic team obtained good reputation in China and worldwide.

D. Achievement & Awards

1. Tangchun Wu, Miao Yang, jing Yuan, Chengfeng Xiao, Feng Wang. The roles of HSPs in environmental stress an environment-related diseases. Natural Science Award in Hubei Province, First Prize, 2009

2. Tangchun Wu,et al. Role of HSPs and DNA repair gene in environmental stress an diseases. National Natural Science Award, Second Prize, 2013

3. Weihong Cheng, Tangchun Wu, et al. Pathogenic development and preventive strategies of industrial dust. National Scientific and Technological Progress Award, Second Prize2014.

4. Tangchun Wu, Kedi Yang, Liegang Liu, Guoyuan Cheng, Ping Yao. Innovation and practice of the training model of preventive medical talents based on ability trainingNational Teaching Achievement AwardSecond Prize2014.

 

 


Prof. XU Shunqings Team

---- Environmental Exposures and Children Health

 

A. Introduction of the Team

Academic Leader: Prof. XU Shunqing

Tenured professor of Occupational and Environmental Health, the Deputy Dean of School of Public Health, Changjiang Distinguished Professor, member of New Century Excellent Talents Project, winner of State Council Expert for Special Allowance and Principal Investigator (PI) of a Key Project of National Natural Science Foundation of China (NSFC). He graduated from Hunan Medical College in 1988 and gained his bachelor degree of Preventive Medicine and received his PhD in 1993 at Tongji Medical College. Dr. Xu’s research is mainly focused on the mechanisms of environmental pollution on human health and relevant bio+markers. Currently, he is leading a Key Project of NSCF to investigate the risks and influences of developmental programming of metabolic diseases induced by embryonic exposure to environmental endocrine disruptors and serving as PI of the Healthy Baby Cohort (HBC), a prospective prenatal cohort study in Wuhan, China. Dr. Xu has published over 100 original papers which published in SCI-collected journals including Lancet Planet Health, Environ Health Perspect, Environ Int, Environ Sci Technol, and Diabetologia. Dr. Xu is the recipient of the Provincial and Ministry of Education Science and Technology Progress Award for many times.

Team Members

Prof. Dr. LI Yuanyuan, Professor of Environmental Health, research interest focuses on the effects of environmental exposures on pregnancy-induced diseases and children development and the corresponding mechanisms, coordinate of a key project to investigate the risks and influences of the blood pressure of pregnant women and hypertensive disorders in pregnancy induced by atmospheric pollution, published 30+ original papers in SCI-collected journals.

Prof. Dr. XIA Wei, associate professor of Environmental Health, principal investigator of a project supported by NSEC, research focuses on the effects of environmental exposures on children development and health (especially metabolic diseases and neurodevelopment disorders) and the corresponding mechanisms, has published 20+ original papers in SCI-collected journals.

B. Main Research Areas

Relationships between environment factors, gene, epigenetic factors and fetal growth and child development and long-term health effects.

C. Background & Significance

With the changes of social, economy and environment, the occurrence rates of various adverse health outcomes of infants and children are rising with each passing year. The impact of environmental factor on the occurrence and process of infant and children adverse health outcomes are unneglectable. Environmental pollutants such as environmental endocrine disrupting chemicals can increase the risk of children metabolic disorders (obesity, hypertension), neurodevelopmental disorders (autistic disorder, attention deficit hyperactivity disorder), and respiratory system allergic diseases (wheeze, asthma). The embryonic phase and neonatal stage are important periods of rapid growth and development of organs and systems. The immature metabolism system, nervous system and respiratory system can be highly sensitive to any external factors which may interfere with development process. Adverse environmental exposures during early life, such as exposure to environmental endocrine disruptors, maternal malnutrition, maternal obesity, tobacco use during pregnancy, infection, endocrine disorder and psychological trauma, can pose a threat to the health condition of infants and children and increase the risk of various diseases in the childhood.

The primary condition of the prevention is to elucidate the pathogenesis and mechanism of the diseases. Birth cohort is the best platform to investigate the pathogenesis of children related diseases, the physical and neural development of children, pregnancy, and children’s health care. The research conclusions of long-term cohort study are highly reliable and have important theoretical and practical significance. In order to provide fundamental basis for improving the health condition of the next generation and scientific basis for controlling environmental pollution, we build up an on-going birth cohort with more than 20,000 mother-infant pairs to explore the effect and mechanisms of adverse environmental exposures in early life with the development and progression of diseases. Adverse pregnancy outcomes, pregnancy complications, childhood diseases, physical and neural development of children are included as outcomes of our study.

D. Academic Strength:

The Healthy Baby Cohort (HBC) is a large-scale prospective birth cohort co-established by the School of Public Health, Huazhong University of Science and Technology, Women and Children Medical and Healthcare Center of Wuhan and Brown University which is committed to investigate the associations between environment factors, gene, epigenetic factors and fetal growth and child development and long-term health effects. This cohort enrolled mother-infant pairs at three maternity hospital in Wuhan (representing for big city), Ezhou (representing for small-medium city), and Macheng (representing for countryside), which are located in Hubei Province in central China. The basic information, health condition, prenatal environmental exposure, maternal healthcare of pregnant women, as well as exposure and health condition of their infants were collected in detail. We also collected and preserved the biological samples of mother-infant pairs at certain time points. Until the end of December 2017, we have recruited 22723 pregnant women, and 17671 single live births were born. More than 1,000,000 specimens were stored in our biobank.

Our school has a Key laboratory of Environment and Health (Wuhan), Ministry of Environmental Protection. The mission of the Key laboratory is to study the relationship of environment and health, focus on factors of environmental pollution. For a long time, the Key laboratory has been working on the studies of the effects and mechanism caused by environmental pollutants to public health and environment, as well as the risk estimate and strategy for prevention. The Key laboratory has a Research Center for Environment and Health which was built in 2005. The area of this center reaches 8,000 square meters, which has minus 80°C freezers equipped with advanced temperature monitoring alarms, and many instruments and equipment including PCR thermocycle instruments (regular and real-time), HPLC-MS/MS, GC-MS, refrigerated centrifuges, automatic enzyme-linked immunosorbent assay systems, digital UV imaging systems, fluorescence microscope, transmission electron microscope, fluorescence spectrophotometer, and UV-VIS Spectrophotometer. The total value of the instrument and equipment reaches up to 36,8 million. Routine experiments and services contain blood/tissue specimen processing, DNA/RNA extractions, protein extraction, genotyping, RNA expression assays, DNA methylation analysis and protein analysis with commercial ELISAs.

Funds: The Healthy Baby Cohort study was supported by five national-level scientific research projects, including one Key Project of National Natural Science Foundation of China, two Major Research Plan of National Natural Science Foundation of China, one Key Project of Reproductive Health and the Prevention and Control of Major Birth Defects, and one Key Project of National Research and Development. The total funding reaches 13 million.

E. Domestic and international cooperation:

The Healthy Baby Cohort study has become an important platform of international academic communication and cooperation of the School of Public Health by establishing strategic partnerships with Yale University and Brown University. Each year we organized regular international academic communications, professors from Brown University come to visit once or twice per year. In 2015, the founder of the project visited Brown University for academic communication. From 2014 to 2016, two academic backbones of the project were sent to the United States for professional development (last for more than one year). Academic cooperations were started in 2014 with Hong Kong Baptist University, and regular academic communications concerning the detection of the pollutants were organized.

 

 

 


Prof. LU Wen-qing ’s Team

----Environmental Chemical Exposures and Human Reproductive Health

 

A. Introduction of the Team

Academic Leader: Prof. LU Wen-qing, Ph.D in Heidelberg University in German, a full Professor specialized in Occupational and Environmental Health of Huazhong University of Science and Technology (HUST), research interests focus on the field of environmental exposures and human reproductive health. Prof. LU is appointed to be the Deputy Director of Environmental Health Professional Committee of Chinese Preventive Medicine Association (CPMA) and a member of Advisory Group of Standards for Drinking Water Quality by the National Health and Family Planning Commission of China. She also won several domestic and international prizes.

Team Members:

Prof. LIU Ai-lin, Ph.D in Huazhong University of Science and Technology (HUST), an associate professor in HUST, specialized in Environmental Health, research interests focus on identifying, evaluating, and controlling environmental conditions that may have an adverse impact on human health.

Prof. ZENG Qiang, Ph.D in Huazhong University of Science and Technology (HUST), an associate professor in Occupational and Environmental Health of HUST, research interests focus on the effects of exposure to environmental chemicals on human reproductive health. Specific health endpoints of interest include male reproductive health and adverse birth outcomes.

Dr. WANG Yi-xin, Ph.D in Huazhong University of Science and Technology (HUST), post-doctor fellow in HUST, specialized in environmental exposure and human reproductive health. He is in charge of the National Postdoctoral Program for Innovative Talents and has published 12 SCI research papers as first author.

B. Main Research Areas

1. The effects of exposure to environmental chemicals on male reproductive health.

2. The effects of exposure to environmental chemicals on adverse birth outcomes.

3. Exposure assessment and predictors of environmental chemicals.

C. Background & Significance

1.Background: Decline in human reproductive health during the past several decades, as a serious public health warning, has been an increasing concern worldwide. Mounting evidence have suggested that exposure to environmental chemicals may play an important role in declining human reproductive health.

2.Academic Strength: We utilize biomarkers of exposure and sensitive reproductive health endpoints to examine the associations between exposure to environmental chemicals and human reproductive health. Several cohort studies including male reproductive health and prospective birth cohort have been established.

3.Domestic & International Influence: We have found that environmental exposure to specific chemicals such as drinking water disinfection by-products, phthalates, and metals are associated with decreased semen quality and/or adverse birth outcomes. These findings have been published in top peer-reviewed journal of environment and health such as Environ Health Perspect, Environ Int, Environ Sci Technol, etc. Among them, some results have been cited by the World Health Organization-International Agency Research Cancer to evaluate the cancer risk assessment of certain environmental chemicals. Also, we have published a monograph on Water Pollution and Health to increase the public’s health consciousness on water safety.

D. Achievement, Awards, Publications

1. Lu WQ, Liu AL, Zeng Q, et al. Toxicity, health risks and evaluation systems of typical pollutants in water. Science and Technology Progress Award in Hubei, First Prize, 2017.

2. Wang AG, Lu WQ, et al. Studies on health risk and toxicity mechanism of topical persistent organic pollutants. Natural Science Award of Ministry of Education in China,   Second Prize, 2012.  

 

 


Prof. LIU Liegang’s Team

---- Nutritional Epidemiology & Gene-Environment Interactions

A. Introduction of the Team

Academic Leader: Prof. Dr. LIU Liegang

Team Members: YANG Wei , SHAN Zhilei Shan, LUO Cheng , CHEN Sijing, SUN Taoping, HUANG Hao, CHEN Liangkai, LI Peiyun, ZHOU Li, YIN Jiawei, PENG Xiaobo, PENG Zhao.

B. Main Research Areas

1. Nutritional epidemiology and prevention of obesity and type 2 diabetes.

2. Gene-environment interactions, biomarkers, and type 2 diabetes.

C. Background & Significance

1. Background

Non-communicable chronic diseases are the leading causes of death and disability worldwide in contemporary population. Among them, diabetes mellitus is a risk factor for various cardiovascular and cerebrovascular diseases, and the disability and mortality rates of diabetic complications are considerably high. Diabetes has emerged as a major public health problem that severely endangers the health of Chinese residents. China presents the largest diabetes population in the world, and the number continues to increase. The latest research published in JAMA in June 2017 suggested that the prevalence of diabetes and prediabetes among Chinese adults is 10.9% and 35.7%, respectively. The prevalence was more than 10-fold than the prevalence reported in 1980s in China. These data underscore the urgent need to identify risk factors and develop effective intervention strategies to curb the alarming diabetes epidemic in China.

2. Academic Strength

Department of Nutrition and Food Hygiene of the School of Public Health is supported by Key Laboratory of Environment and Health of Ministry of Education and Key Laboratory of Food Nutrition and Safety of Hubei Province. As a main component of the Research Center for Environment and Health of School of Public Health, the center relies on State Key Laboratory (cultivation) co-founded by Hubei Province and Ministry of Education, Key Laboratory of Environmental Hygiene, Key Laboratory of Environmental and Health of Ministry of Education and Key Laboratory of Environment and Health of Ministry of Environmental Protection. In recent years, the center has received over 40 million yuan from the "985 Project" and "211 Discipline Construction Project" of the Ministry of Education, and has completed the construction of molecular toxicology laboratory, molecular epidemiological laboratory, environmental epidemiology laboratory, environmental monitoring laboratory, occupational monitoring laboratory and many other functional laboratories. Research Center for Environment and Health covers 8,000+ square meters as experimental space, and has purchased 50+ items of large-scale expensive equipment, including genetic analyzer, fluorescence quantitative PCR instrument, protein interaction array system, liquid chromatography-tandem quadrupole mass spectrometer, plasma spectroscopy-mass spectrometer, medium-throughput genotyping system, and high-throughput genotyping system, etc. In addition, the research center has built up 5 biobanks and owned 400+ ultra-low temperature freezers for long-term storage of biological samples.

The team has established a biobank of 3,000+ pairs of cases with newly diagnosed diabetes and controls with normal glucose tolerance. In cooperation with Ezhou CDC, prospective cohort in Ezhou has been built up and baseline data and biological samples acquired for over 10,000 participants.The biobank contained plasma, white blood cells, red blood cells, lymphocytes, and feces etc. The team took advantage of Tongji research center to detect the biomarkers of the samples using LC-MS/MS, GC-MS/MS, and ICP-MS, etc. Compared with traditional questionnaires and dietary surveys, these methods analyze the exposures and the development of diseases in a more accurate way.

Further, the team has wide-ranging contacts and participates in the establishment of multi-center cohorts to investigate the relationship of the gene-environment interactions and novel biomarkers with type 2 diabetes. Extensive research were done on dietary factors, such as trace elements (iron, vanadium, zinc, selenium, manganese, and chromium), eggs, dietary fibers, nuts, trimethylamine oxides, and advanced glycation end-products, and type 2 diabetes.

3. Domestic & International Influence

Research interests focus on evidence-based medicine and epidemiology. Our studies have been published in British Medical Journal (BMJ), Diabetes Care, American Journal of Clinical Nutrition (AJCN), and American Journal of Epidemiology (AJE) etc. Team members have been invited to several international conferences to present our results.One of our articles "Egg consumption and risk of coronary heart disease and stroke: dose-response meta-analysis of prospective cohort studies" published in BMJ suggested that eating one egg per day did not increase the risk of coronary heart disease and stroke in healthy adults, but it reversed in diabetic population. The result was highly praised by peer experts and The New York Times. Another publication "Plasma Alkylresorcinol Metabolite, a Biomarker of Whole-Grain Wheat and Rye Intake, and Risk of Type 2 Diabetes and Impaired Glucose Regulation in a Chinese Population" in Diabetes Care in December 2017, provided a supporting for the beneficial effect of whole-grain in preventing type 2 diabetes. Further, it revealed that dietary biomarkers might be a more reliable and more objective tool for research compared to traditional dietary surveys, which providing a bran-new way for nutrition epidemiology.

D. Achievement, Awards, Publications

Awards: Ministerial (provincial) The Second Prize of Technology Progress

Publications (corresponding author): Over 80 articles in peer-reviewed journals, including BMJ, Diabetes Care, Environmental Health Perspectives, Diabetes, American Journal of Clinical Nutrition, and American Journal of Epidemiology, etc.

 

 


Prof. Miao Xiaoping’s Team

---- Cancer Molecular Epidemiology

 

A. Introduction of the Team

Team Leader: Prof. Miao Xiaoping, Ph.D, Associate Dean of the School of Public Health, Huazhong University of Science and Technology. He took postgraduate education and got PH.D. Degree from Peking Union Medical College (PUMC) and has been trained as a postdoctoral fellow and honorary assistant professor in the University of Hong Kong in the area of genetic epidemiology.  

窗体底端

Team Members:

Dr. Chang Jiang, Ph.D in Peking Union Medical College, associate professor of the School of Public Health in TMC. He was devoted to the large scale and multiple centers based molecular epidemiology study on human digestive system cancers. More detailed information see: http://gwxy.tjmu.edu.cn/info/1087/1841.htm.

Dr. Zhong Rong, Ph.D in school of public health of TMC, associate professor of Epidemiology, research interests focus on non-communicable diseases, such as cancer and NAFLD. Detailed information: http://gwxy.tjmu.edu.cn/info/1087/1799.htm

Dr. Gong Jing, Ph.D, an associate professor of Biostatistics in school of public health, TMC, academic areas specialized in biological big data mining. Detailed information: http://gwxy.tjmu.edu.cn/info/1087/1797.htm.

 

B. Main Research Areas

The major area of research interest is molecular epidemiology and genetic epidemiology. We apply a variety of molecular epidemiological and biochemical approaches to investigate the associations between genetic variants and susceptibility to common cancers, with an emphasis in characterization of biological functions as the underlying molecular mechanisms. Our major academic achievements in recent 5 years include: 1. We firstly completed a genome-wide association study of pancreatic cancer and an exome-wide analyses of esophageal squamous cell carcinoma in Chinese population, which has advanced our understanding of the development of cancer and highlight potential targets for the prevention or treatment of these two cancers. Notably, both of studies were published in Nat Genet. 2. We developed several strategies to investigate gene-environment and gene-gene interactions in the role of cancer susceptibility, which has promote the development of molecular epidemiology, especially in cancer. This part of work has been honored the second prize of Hubei Natural Science Award. 3. We integrated molecular epidemiological and biochemical approaches to dissect the biological mechanisms underlying the associations between genetic variants and risk of cancer, which might increase the power of cancer prediction. In recent 5 years, we has published more than 50 papers as correspondence author in the SCI journals, including Nat Genet, Nucleic Acids Res and Carcinogenesis, of which 4 were selected as ESI highly cited papers and other 4 were IF>10.

C. Background & Significance

Molecular epidemiology is a branch of epidemiology and medical science that focuses on the contribution of potential genetic and environmental risk factors, identified at the molecular level, to the etiology, distribution and prevention of disease within families and across populations. This field has emerged from the integration of molecular biology into traditional epidemiologic research.  Molecular epidemiology improves our understanding of the pathogenesis of disease by identifying specific pathways, molecules and genes that influence the risk of developing disease.

D. Achievement & Awards

5. Miao Xiaoping, Chang Jiang, Zhong Rong, Liu Li, Zhu Beibei. Gene-environmental interaction and susceptibility of common digestive cancers. Second Prize of Hubei Natural Science Award, 2017


Prof. CHEN Weihong’s Team

---- Occupational and Environmental Epidemiology

 

A. Introduction of the Team

Team Leader: Prof. CHEN Weihong, M.D, Professor and Director of the Department of Occupational and Environmental Health at the School of Public Health, TMC, member of New Century Excellent Talents Project, the Key Laboratory of Environment and Health, Ministry of Education and State Key Laboratory of Environmental Health (Incubating). Prof. Chen graduated from the School of Public Health at TMC and obtained bachelor degree of medicine and master degree of Public Health. She gained doctoral degree of medicine in the Medical College of Essen University in Germany. She is adjunct professor at the Chinese University of Hong Kong. More detailed information see: http://english.tjmu.edu.cn/info/1076/1166.htm

 

窗体底端

Team Members:

Prof. YUAN Jing, Ph.D., Professor and Director of the Department of Occupational and Environmental Health at the School of Public Health, TMC. She received her PhD degree at the Ulm University, Germany. Her research interests focus on risks and potential pathogenesis of environmental pollutants including particular matter, PAHs, persistent organic pollutants exposure on human health. She has published extensively in the area of environmental health and received several large funds and also awards of Hubei Province on this topic. More detailed information see: http://english.tjmu.edu.cn/info/1076/1205.htm

Associate Prof. LIANG Yuan, Ph.D., Department of Social Medicine and Health Management, Public Health School, TMC. He received his PhD degree at Huazhong University of Science and Technology, China. His research interests focus on social determinants of health, organizational behavior and chronic disease management. As PI, he directed several national and international research projects, including National Major Research Program National Major Research Program of China, National Natural Science Foundation of China as well as China Medical Board. More detailed information see: http://gwxy.tjmu.edu.cn/info /1087/1816.htm

Dr. Yun Zhou, Ph.D., Lecturer in the Department of Occupational and Environmental Health at the School of Public Health, Tongji Medical College, Huazhong University of Science and Technology. She received her PhD degree in 2017 at TMC. Her research interests focus on the associations between environmental pollutant exposures and respiratory disorders such as lung function decline, COPD or asthma, as well as potential mechanisms involved in the associations. She has published 28 SCI papers, such as Am J Respir Crit Care Med, Environ Int, Environ Pollut, Am J Epidemiol, and Arch Toxicol, including 9 papers as the first author.

The other two members includes Dr. GUO Yanjun and Dr. Ma Jixuan.

B. Main Research Areas

The research term focused on the health effects, potential mechanism and preventive strategies of environmental pollutants, especial particulate matter.

The main research topics include:

2. Health effects (on human) of particulate matter and persistent pollutants exposure, especially pay attention to health damage of respiratory system, metabolic and endocrine system.

3. The pathogenic mechanism by which environmental pollutants such as particle matter induce cardiopulmonary or metabolic damage.

4. Environmental exposure monitoring of pollutants and evaluation of personal respiratory protection equipment.

 

C. Background & Significance

This academic team established the cohort of crystalline silica exposed workers, which is reported to be the largest reliable cohort in this research field. The cohort included 74040 workers from 29 metal mines and pottery factories and were followed up from 1960 to the end of 2003, with median follow-up of 33 years. Significant positive exposure-response relationships existed between respirable silica exposure and risk of silicosis, the mortality from all causes, respiratory diseases and cardiovascular disease. The findings of cohort study confirmed crystalline silica as a human carcinogen and observed joint effect of silica and smoking on lung cancer. These results were used to revise national exposure limitation of silica dust in the workplaces.  

Another cohort, the Wuhan-Zhuhai cohort was established in 2012 and finished the first and second follow-up in 2015 and 2018 by this team. This cohort is a community-based prospective study that includes 4812 residents from Wuhan city and Zhuhai city at baseline. In addition to questionnaire on personal life habit, job history and disease history, personal physical and health examination, the environmental air particulate matters, PAHs and internal urinary PAHs, metals were determined. The results obtained in WHZH cohort study may increase a better understanding of the relationship between particulate air pollution and its components and possible health damages. And the potential mechanisms underlying the development of cardiopulmonary diseases has implications for the development of prevention strategies.

D. Achievement & Awards

6. Weihong Chen, Tangchun Wu, Lei Yang, Lieya Xie, Jie Chen, Jingqiong Chen, Dexun Yu, Yuewei Liu, Qincheng He, Jiezhi Lou. Pathogenic development and preventive strategies of industrial dust. National Scientific and Technological Progress Award, Second Prize, 2014.

7. Weihong Chen, Jingqiong Chen, Leiyang, et al. The cohort study of dust exposed workers. Scientific and Technological Progress Award in Hubei Province, First Prize, 2007

8. Aiguo Wang, Wenqing Lu, Jing Yuan, Kedi Yang, Zhenzhen Wang. Studies on the toxic effects of typical persistent organic pollutants and their underlying mechanisms. Natural Science of Hubei Province, First Prize, 2013

9. Weihong Chen, et al. Classification of occupational hazards at workplace Part 1: occupational exposure to industrial dust. National Occupational Health Standards, 2010-10-01

 


Prof. ZHANG Yonghui ’s Team

----Medicinal Chemistry and Innovative Drugs Development

 

  1. Introduction of the Team

    Team Leader: Prof. ZHANG Yonghui, dean of School of Pharmacy. He has awarded several titles including Distinguished Young Scholars of NSFC (2017), Changjiang Scholars of Ministry of Education of China (2016), the Innovation Leading Talents of National "10,000 People Plan" in Science and Technology (2017), and the Innovative Leading Talents in Science and Technology (2016). He is also the Director of the Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation and the associate editor of Natural Medicinal Chemistry 2016 published by People's Medical Publishing House (PMPH). His major research interests focus on Natural Medicinal Chemistry and Innovative Drugs Development.

    Team Members:

    Prof. XUE Yongbo, specialist in Active Natural Products from Medicinal Plants and Fungi.

    Prof. WANG Jianping, focus on natural medicine resources.

    Prof. LUO Zengwei, expert in natural products organic synthesis.

    Prof. ZHOU Qun, focus on pharmacological activity of natural products and its mechanism of action.

    Prof. ZHOU Yuan, specialist in natural medicine chemistry and synthetic biology.

    Prof. ZHU Hucheng, focus on Active Natural Products from Medicinal Plants and Fungi.

    Dr. CHEN Chunmei, specialized in Active Natural Products from Medicinal Plants and Fungi.

  2. Main Research Areas

    1. Novel secondary metabolites from fungi and their bio-activities.

    2. PPAPs from the genus Hypericum and their bio-activities.

    3. New drugs or health products derived from a rare and precious traditional Chinese medicine Anoectochilus roxburghii.

  3. Background & Significance

    Natural products are important secondary metabolites of plants and microorganisms produced during their long-term evolution and adaptation to the environment, which help them to compete with other species and resist insect infestations. Meanwhile, natural products are the most important source of new drugs as more than 60% of the small molecule drugs are derived directly or indirectly from natural products since 1981. The 2015 Nobel Prize in Physiology or Medicine was awarded by You-you Tu for her great contribution to the research of Artemisinin from the traditional Chinese medicines, which shows that there is still a brilliant future for natural product research!

    There are four main research areas of our group, including the discovery of active natural products, the pharmacodynamics and mechanism of natural products, the biosynthesis of active natural products, and the structure-activity relationship of natural lead compounds. We devote ourselves to the study on the secondary metabolites of more than twenty kinds of fungi such as Aspergillus, and more than thirty kinds of medicinal plants such as Hypericum distributed in central China. So far, more than 2000 active natural products including cytochalasans, terpenoids, and PPAPs, have been isolated and identified, and over 800 of them are new ones, including 65 compounds with new carbon skeletons, which belonging to 32 different new framework types. Notably, nine of the isolated compounds were rated as hot off the press by Nat. Prod. Rep., and more than ten natural products or derivatives are potential for drug development. We have obtained remarkable achievement in the area of the identification and activity evaluation of complex and trace natural products, the pharmacology and mechanism of the active compounds.

  4. Achievement, Awards, Publications

    The team has won all kinds of research projects with total funds 40+ million Yuan, published more than 90 SCI papers in recent 5 years, including Angew. Chem., Int. Ed. (4 articles), Hepatology (1 article), Chem. Sci. (1 article), Org. Lett. (11 articles). In addition, our group have held many international conferences, including co-chaired the “Sino-German international Conference on Natural Products”(2015) and “Sino-German-Marburg Pharmaceutical Summit” (2017), and also made some speeches on international conferences. Prof. Zhang now serves as the associate editor of “Current Medical Science", and still serves on the editorial boards of “SCI-REP”, “Journal of Pharmacology”, and “Pharmaceutical Progress”, etc.

     

     

     

    Prof. HUANG Kun ’s Team

    ---- Diabetes Drug Development

     

  5. Introduction

    Principal Investigator: Prof. Dr. HUANG Kun, Ph.D, New Century Excellent Talents of Ministry of Education, Distinguished Young Scholar of NSFC, with research interests focus on the drug development of diabetes based on biotechnology, proteomics and metabolomics of metabolic diseases, and mechanism and gene therapy study of carcinogenesis.

    Team Members:

    Prof. Dr. LIU Xinran, associate professor, focuses on oncogenic molecular pathways of liver and lung cancer.

    Dr ZHANG Yu, lecture, research interests focus on the molecular mechanism of the crosstalk of inflammation and metabolic diseases.

    Dr CHEN Hong, lecture, focuses on the mechanism and therapy for diabetic complications.

  6. Major Research Interests

    drug development of diabetes based on biotechnology, proteomics and metabolomics of metabolic diseases, and mechanism and gene therapy study of carcinogenesis.

  7. Achievement

    They have published over 70 peer-reviewed papers in prestigious academic journals, such as Hepatology, Journal of Hepatology, Nature communications, Autophagy, Journal of American Society of Nephrology, PNAS, Diabetes, Cancer Research and Journal of Physiology. They discovered Apelin/Elabela-APJ and H1.2 as novel therapeutic targets of diabetic nephropathy, which relieve the symptom through regulating blood glucose, autophagy and vasoconstricition. They also reported that maternal metabolic obesity may pass on to the offspring, and metabolic and mitotic regulators GAPDH and MPP1 play critical roles in HCC through metabolic dysregulation. The team also studied and developed multiple of novel therapeutic proteins/peptides and strategies against diabetes and cancer, moreover, they also discovered multiple of leading peptides/compounds of good druggability, and the translational research is under investigation.

     

     

     

     

     

     



    ZHANG Liang’s Team

----Rural Health Care Development

 

A. Introduction of the Team

Academic Leader: Prof. Dr. ZHANG Liang, a professor (second grade) and Ph.D. tutor from School of Medicine and Health Management, is also the vice chairman of the Chinese Rural Health Association, and the leader of a Key Program of National Natural Science Foundation.

Team Members:

This team consists of 2 professors, 5 associate professors, and 4 lecturers, namely, Prof. FENG Zhanchun (the Dean of School of Medicine and Health Management), Prof. CHEN Yingchun (Hubei Research Center for Rural Health Service), Associate Prof. ZHANG Xiang, Associate Prof. Zhang Zhiguo, Associate Prof. WANG Jing, Associate Prof. XIONG Juyang, Associate Prof. GAO Hongxia.

B. Main Research Areas

The research team focuses on rural health policies and innovative health care delivery, whose research fields contain the promotion of health care capability, integration of health care, health care performance, public health and health insurance:

1.Primary health care delivery, Includes the design of health delivery system, the integration of health delivery system, capability improvement of health care institutions, standardization of provider’s performance, assessment of organization’s performance, health care utilization of residents, health care quality assessment, health policy assessment, etc.

2.Public health policy and management, includes public health system, performance improvement of public health, public health financial policy, management and service optimization of chronic diseases and infectious diseases.

3.Rural health governance, includes the payment reform, the integration of health insurance and health services, the mechanism of payment to providers’ behavior, the provision of excessive medical care by doctors and the use of irrational services by residents.

4.Health care utilization of disadvantaged people, includes health care utilization, risk assessment, quality of life, and social network support for the poor, the elderly, and the patients with mental illness.

5.Health informatization, mainly includes the big data monitor, the analysis technology of health big data, the transformation of service delivery supported by informatization, and the health management based on mobile Internet technology and health big data.

C. Background & Significance

Rural health care system is the cornerstone for the realization of universal primary care. The county-township-village health care system determines the health care utilization of 760 million residents in rural China. With the increasing demand for qualified and diversified health services, the rural health care system are facing challenges. However, there are quite a lot of problems in present system, such as fragmented supply system, homogeneous competition among health care institutions, ineffective public health services, etc., intensifying the inequity and economic risks of health care utilization. At the same time, the health insurance is also faced with issues like fund overdraft.

Prof. ZHANG Liang and Prof. FENG Zhanchun have been paying attention to rural health care issues since they presided over a World Bank project on primary care in rural China in 2003. They have contributed to the construction of the new Rural Cooperative Medical System and put forward the framework of performance evaluation for primary care organizations, etc. Thereafter, they have carried out plenty of researches on health care policies and applications. They have set up research teams on health delivery, public health performance, health insurance, rural health policy, payment reform, and so on, and they advanced some new research areas in rural health care development such as health integration, NCD management and health and poverty alleviation.

D. Achievement, Awards, Publications

The research results have won the Health Policy and Management Award from the Chinese Medical Association, Hubei science and Technology Progress Award. The research team has won the total research project fund for over 10 million yuan, and published 14 academic monographs and more than 600 research articles, including more than 100 SCI/SSCI. And more than 70 doctoral students and 100 graduate students have graduated from the research team.

 



Prof. HU Yu’s Team

----Hematology Diseases

A. Introduction of the Team

Within the current 154 medical and technical staff, there are 30 active professors and associate professors, 15 doctoral supervisors and 14 master’s supervisors, 1 Yangtze River Scholar and Distinguished Professor of the Ministry of Education, 2 recipients of National Science Fund for Distinguished Young Scholars, 1 recipient of the National New-century Talents project, 3 recipients of outstanding doctoral thesis awards of Hubei Province. 50% of our staff have studied abroad, and 70% of the physicians have PhD degrees.  

Team Leader: Prof. Dr. HU Yu, Doctor of Medicine, professor, chief physician, doctoral supervisor, Director of department of hematology and institute of hematology, President of Union Hospital, Tongji Medical School, Huazhong University of Science and Technology.

Dr. Hu has undertaken 21 national and provincial research projects. He is also the leader of the following projects: one of Major Projects for "Significant New Drugs Development" of the Ministry of Science and Technology, subsection of “973 project”, one of the National Outstanding Youth Funding, three of the Key Clinical Projects of the Ministry of Health, one of Innovative Research Team of the Ministry of Education, one of International Cooperation and Exchange programs and five general programs of the National Natural Science Foundation of China. Dr. Hu has been awarded as the New Century talents by State Personnel Board and the Ministry of Education in 2007, and received the National Science Fund for Distinguished Young Scholars in 2009, and rewarded as “Yangtze river scholars” in 2009, Young experts with outstanding contributions by the Ministry of Health in 2012, Leading talent in the national press and publishing industry in 2013.

Team members

Dr. XIA Linghui, Professor, chief physician, doctoral supervisor. Member of Chinese committee of donor bank of hematopoietic stem cells, member of hematology section of Chinese Geriatrics Society, standing committee member of Hematology professional committees of Cross-strait medical and Health Association, member and secretory of Hubei Hematology Association, vice chairman of hematology section of Chinese Interactive Medicine Association, vice chairman of Hubei Biomedical immunology association committee, member of Hubei Transplantation Association.

Dr. GUO Tao, Chief physician, doctoral supervisor, member of Chinese College of Hematology Physicians, member of thrombosis and hemostasis section of Chinese Medical Association, Chairman of Wuhan Hematology Association

Dr. SUN Chunyan, Chief physician, doctoral supervisor, youth committee member of hematology section of Chinese Medical Association, Member of hematological pathology workgroup of Hematologic Malignancies of Chinese Anti-Cancer Association, Standing committee member of Lymphoma section of Hubei Anti-Cancer Association, Member of Wuhan Hematology Association. Dr. Sun specializes in the pathogenesis and targeted treatment of malignant tumors, including myeloma, lymphoma, leukemia and other hematologic malignant diseases, as well as the diagnosis and treatment of myelodysplastic syndromes, aplastic anemia. She has received two funding from National Natural Science Foundation, one from Research Fund Project of Hubei Health Department, and has over 40 publications in national and international journals. She was awarded the first prize of science and technology progress in Hubei Province in 2007 and 2012 respectively.

Dr. WANG Huafang, doctoral supervisor, office director of the hematology institute of Union Hospital, Member of transplantation section of Wuhan Medical Association, Registered physician of Hubei Diagnosis and Treatment center for Hemophilia of World Federation of Hemophilia, Editor of Thrombosis Haemostasis, English proofreader of Clinical hematology.

Dr. MEI Heng, deputy chief physician, Master’s supervisor, Member of hematology section of Chinese Geriatrics Society, Member of biotherapy section of Chinese Research Hospital Association, Standing committee member of Experimental Hematology section of Chinese Association of Pathophysiology, Youth committee member of Internal Medicine section of Chinese Medical Association Dr. Mei specialized in clinical diagnosis and treatment of hematological diseases, especially in the treatment of malignant hematologic diseases and the diagnosis and treatment of complex and complicated blood coagulation disease. His research focuses on CAR-T therapy for hematological malignancies and the innovative diagnosis and treatment of DIC. Dr. Mei has spent 2 years for advanced studies in one of the hospitals in the US, directed 6 of national and provincial and ministerial research programs, published more than 20 clinical research papers, undertook 4 national and international clinical research programs. He has received 1 patent, first prize of scientific and technological progress of the Ministry of Education in 2015 and first prize of Hubei science and technology achievement promotion.

Dr. SHI Wei, deputy chief physician; specializes in hematological malignancies, complex haemorrhage and coagulation disorders and hematopoietic stem cell transplantation, published 20+ SCI papers, 5 of which have over-5 impact factor.

Dr. TANG Liang, medical doctor, attending physician; published 19 SCI papers as first or correspondence author.

B. Research Interest

By taking advantage of modern diagnosis and treatment technologies, we have enhanced the accuracy of diagnosis and classification of hematologic malignancies and other diseases, as well as the competence of blood diseases diagnosis and treatment in Hubei province and even the entire southwest and central China. We specialize in hematopoietic stem cell transplantation, thrombosis and hemostasis, multiple myeloma, leukemia, immunotherapy (CAR-T). We also have reached international level of excellence in the treatment of blood diseases including leukemia, lymphoma, multiple myeloma, and blood coagulation diseases.

C. Research Achievements

In the past five years, our department has stayed at the 5th or 6th in the three major rankings in China. There are 44 National Natural Science Foundation projects from 2011 to 2017, as well as over 60 projects including special project of “Significant New Drugs Development" of the Ministry of Science and Technology, Innovative Team of the Ministry of Education, National Science Fund for Distinguished Young Scholars, subsection of national “973” project, National Key Scientific and Technological project, with total funding of almost 50 million. We also have over 10 evaluation projects, most of which are at top level domestically or abroad. Within 236 SCI publications, 54 have impact factor over 5, and 3 over 10. As the first applicant, Dr. Hu have applied for 3 patents, one of which got certified. The provincial and ministerial awards are lists as follows:

Year

Awards

Projects

2017

First prize: Hubei science & technology achievement promotion

Early diagnosis and targeted investigation of thrombotic diseases

2016

First prize: Scientific & Technological Progress of the Ministry of Education

Early diagnosis and targeted investigation of thrombotic diseases

2012

First prize: Scientific & Technological Progress of Hubei Province; First prize: Scientific & Technological Progress of Wuhan City

Experimental and clinical investigation of multiple myeloma

2007

First prize: Scientific & Technological Progress of Hubei Province; First prize: Scientific & Technological Progress of Wuhan City

The function and targeted intervention of tissue factor in thrombotic and non-thrombotic diseases

2005

Second prize: nominated for the Scientific & Technological Progress of the Ministry of Education

First prize: Scientific & Technological Progress of Hubei Province

Early diagnosis and clinical application of disseminated intravascular coagulation

 

D. Advantages and Resources

In Union Hospital, this team is in charge of 6 labs with a total area of over 800 square meters. The thrombosis and hemostasis clinical research center of Hubei Province has research and technical staff and all facilities, including ultra-low temperature refrigerator, low-temperature centrifuge, Gel Imager, real-time quantitative PCR, protein electrophoresis device, cell culture equipment, confocal microscope, Flow cytometry, Macromolecular Interaction Instrument (SPR) and others. Annually, 20 graduate students could get training here. There is a GMP-certified cell culture lab in the Hubei clinical research center of cell therapy of malignancies. We have established a whole set of CAR-T Immunotherapy, and initiated clinical trials. So far, over 30 cases of refractory-relapsed leukemia have been treated successfully. The molecular diagnosis platform of hematologic diseases has been authenticated by international standardization organization (ISO) led by Peking University. With annual tests of 5000 cases, it has become the gold standard for gene diagnosis in hematology department of major hospitals in southwest China. Among them, the diagnosis platform of thrombophilia, the molecular diagnosis of 9,978 patients was performed in 26 hospitals nationwide, and the etiology of thrombosis was identified for 2,115 patients. The annual outpatient service was more than 80,000, the number of inpatients was more than 7000, the efficiency of diagnosis and treatment was over 95%, and patient satisfaction rate reached 98%.

 

 

 


Prof. WANG Guobin’s Team

----Gastrointestinal Diseases

 

 

A. Team Introduction

The minimally invasive surgical clinical research center led by Prof. WANG Guobin, is highly specialized in clinical and basic research organization for gastrointestinal diseases. It is a national key discipline and possesses solid strength in clinical medicine, teaching and scientific research. The research center currently has 3 professors, 7 associate professors. Through years of disciplinary construction, it has formed a well-equipped academic echelon, and its academic research and clinical medical skills are leading in China. Since 2001, Prof. WANG Guobin, director of the center, has conducted on-site surgery demonstration in more than 30 medical institutions throughout China.

Academic Leader: Prof. Dr. WANG Wangbin, former Dean of the Union Hospital; Visiting Professor of Surgery, University of Pittsburgh, USA and Visiting Professor of Humboldt School of Medicine, Saarland University, Germany; Fellow of American College of Surgeon (ACS). Prof. WANG is also the the Director of Translational Medicine Center and Clinical Research Center of Minimally Invasive Surgery, Leading Scholar of The National Key Disciplines (General Surgery) , and National first-class professors, and national special allowance recipients. Chairman or Vice-Chairman of multiple committees and associations in the gastrointestinal medicine and related filed, and chief editor of many domestic or international renowned journals, chief editor of many textbooks and professional reference books. Being the coordinator of many research projects (NSFC) , he published 300+ papers and won 2 first prizes and 3 third prizes in Hubei Province. He also won honors and awards such as "Deputy to National People's Congress", "National Labor Medal", "Chinese Physician Award", "Young Experts with Outstanding Contributions", "Chutian Scholars of Hubei Province".

Team Members:

Prof. Dr. TAO Kaixiong, male, director of General Surgery Department and deputy director of Gastrointestinal Surgery Department of Union Hospital, member of multiple committees and associations in the gastrointestinal medicine and related filed. A famous expert in surgical operation, especially minimally invasive laparoscopy. Being one of the founders of the Laparoscopy Surgical Research and Therapeutic Center, the Clinical Research Center of Minimally Invasive Medicine in Union Hospital, Prof. Tao also possesses the title of editorial for various renowned journals like Gastrointestinal Surgery, Laparoscopy and Chinese Experimental Science etc. He is also the coordinator in charge of multiple major research projects.

Prof. Dr. WANG Zheng, Ph.D in genomics of Duke University,USA, member of multiple committees and associations in the gastrointestinal medicine and related filed, such as Council for Cell Biology, American Board of Medical Genetics and American Society for Cell Biology. As double expert in surgery and genomics , Dr. WANG is specialized in rectal cancer metastasis, has been in charge of multiple NSFC Projects and Hubei Provincial Projects, with 31 SCI-Journal articles published and 11 National Invention Patents owned.

Associate Prof. Dr. CAI Kailin, Ph.D, Chief Physician, Deputy Director of Gastrointestinal Surgery and Endoscopy Center of Union Hospital, member of Nutrition Support Group of Chinese Society of Surgery and many other committees and association in related field, editor of World Chinese Journal of Digestology and Journal of Laparoscopic Surgery. Prof. CAI made postdoctoral researcher in Japan in 2011. He has chaired and participated in research on a number of national and provincial-level research projects, and has published 10+ professional papers in authoritative domestic and international magazines.

Associate Prof. Dr. SHUAI Xiaoming, Ph.D, Chief Physician, member of the Laparoscopy Surgery Professional Committee of China and many other committees and association in related field, a visiting scholar in Kanazawa Medical University in 2014 and an exchange scholar in Rambam Medical Center in Haifa, Israel in 2017. He has chaired and participated in a number of national and provincial-level research projects, with 20 + scientific papers published.

B. Research Interest

clinical treatment and basic research in gastrointestinal diseases, minimally invasive surgery, mainly engaged in the molecular basis of congenital hirschsprung diseases, tumor biology and immunology, cancer surgery and metabolomics research. In-depth studies and exploration on the minimally invasive targeted therapy of malignant tumor in digestive tract.

C. International Influence:

The Center attaches great importance to international academic exchanges, has hosted 5 International Conference on minimally invasive surgery. The American Nobel Prize winner Prof. Feid Murad, the world's leading colorectal cancer center expert Professor Hampshire, Colorectal Surgery Professor Bill Heald, the University of Michigan Professor Michale W. Mulholland, The director of the Department of General Surgery Professor Michael D.Menger from Sarrland University Germany, visited the centers for academic exchanges.

D. Achievement:

In recent years, it has been supported by 1 key project funded by the National Natural Science Foundation of China, 1 project under the State 863 Program, 1 project under National Health and Family Planning Commission special public sector fund and over 10 projects under the National Natural Science Foundation of China. The center's innovative achievements have been commended by the government of the country. It has successively won the first prize of Scientific and Technological Progress Award of Hubei Province, the First Prize of Hubei Provincial Science and Technology Achievement Promotion Award and the Wuhan Municipal Science and Technology Progress Award. In recent years, he has published more than 300 papers, including more than 90 papers published by SCI, and trained over 100 doctoral and master degree students.

 

 

 


Prof. DONG Nianguo’s Team

---- Cardiovascular Diseases

 

A. Introduction of the team

Team Leader: Prof. DONG Nianguo, national-renowned professor, doctoral instructor, winner of the State Council's Government Subsidies, young and middle-aged experts with outstanding contributions recognized by the Ministry of Health, director of Cardiovascular Surgery Department (National Clinical Key Specialty) and the director of the Organ Transplant Center (national key discipline) of HUST. A member of the American Association of Thoracic and Cardiac Surgery (AATS). Editorial Board Member of many prominent medical journals such as the Clinical Cardiovascular Disease, Innovation, International Cardiovascular Disease and Acta Med Univ SciTechnol Huazhong (Med Sci) etc.

Long-term commitment to cardiovascular clinical surgery, scientific research and teaching, performed more than 4,000 heart vessels surgical operation independently in the last five years with low mortality and rare complications, carried out various types of surgical operations on severe infant congenital valve diseases, minimally invasive valve replacement/plastic surgery, bypass surgery, minimal invasive coronary bypass surgery and artificial intelligence robot heart surgery. Especially in 2008, a total of 498 cases of heart transplantation were completed, with 96% survival rate among with 84% survived in five years, no.1 in China regarding the total number of operation in the field, created multiple domestic and international records: the first to carry out the "suboptimal / marginal hearts" surgery application in China, the largest number of heart transplantation in infants (37 cases) among which the youngest infant in Asia(3-month old, 4.25Kg), the world's oldest patient heart transplantation (76-year-old); China’s first and Asia’s third case of heart-liver joint transplantation, ranked forefront in the heart and multi-organ transplantation (4 heart-lung cases, 1 heart-liver case, 1 heart-kidney case) in China.

Team Members

Research Area

Name

Academic Title

New heart valve replacement research and development

SHI Jiawei

Professor

QIU Xuefeng

associate professor

HONG Hao

associate professor

DENG Cheng

attending doctor

SHI Feng

attending doctor

HU Xingjian

attending doctor

QIAO Weihua

attending doctor

Mechanism of Calcified Valvular Heart Disease (CVHD)

CHEN Si

associate professor

LI Fei

attending doctor

ZHANG Qiao

attending doctor

WANG Yin

attending doctor

LI Huadong

attending doctor

LI Geng

attending doctor

CHEN Chong

attending doctor

B. Main Research Areas

1. Research on New Heart Valve Replacement

A series of achievements have been made in the research of tissue engineering----heart valve stent materials, seed cells and their interactions: 1) established high bionic decellularized valve scaffold handling and preparation system 2) proved that biological signal molecules and polymer materials can improve the decellularized valve scaffold’s adhesion and growth on seed cells; 3) be the pioneers in putting forward concepts like "composite stent", "active molecular improvement on biological properties", "stent modification to improve mechanical properties" and "micro-environment simulation" etc. Which were widely recognized by domestic and international counterparts; 4) In the light of the existing biological valve production process, try branched PEG cross-link modification to  construct TEHV with decellularized valve scaffold, and to improve the biomechanics performance.This research has acquired a number of patents in China, and as independent innovation of intellectual property which is expected to convert to clinical application.

2. The Research on Pathogenesis of Calcified Valvular Heart Disease

Creative research and study work on pathogenesis of CVHD: 1) discovered that in the calcified heart valves, the expression of receptor for advanced glycation end products (RAGE) increased and endoplasmic reticulum stress (ER stress) is activated. If the activity of RAGE could be inhibited by drugs or genetically removed, the ER stress could then be inhibited so that the infiltration of macrophage and the calcification in the heart valves could be reduced. 2) discovered that the macrophage participates in the calcification process of the heart valves. 3) discovered that inflammatory factors like HMGB1, IL-18 and IL-1 significantly increased in the peripheral blood of the CVHD patients. HMGB1, IL-18 and IL-1 might not only induce valvular interstitial cells to differentiate into osteoblastic cells, but also induce the calcification of valvular interstitial cells. The level of inflammatory factors in the human peripheral blood might be the biomarker which signals the clinical progress and severity of valvular heart calcification. 4) MicroRNA-204 regulates targeted the activity of osteogenic transcription factors Runx 2 and inhibits the osteoblastic differentiation and calcification of valvular interstitial cells.

C. Resources & Advantages

The Cardiovascular Department of Union Hospital Affiliated to Huazhong University of Science and Technology is the national clinical key specialty and the key subjects of Ministry of Education (specialized in heart transplantation). It is one of the earliest major centers in China performing clinical heart valve surgeries, and stayed forefront among international peers in research and development of heart valve pathology and valve replacement.In 1976, cow's pericardium valve was successfully made by the Center and used for clinical purposes, much earlier among the peers in China, and meanwhile, studies were made on its biological properties and decay mechanism. In 1978, second prize was awarded in the National Science and Technology Conference. In 1995, the Center first indicated the valve leaflet tear is a common cause for cow's pericardium valve failure, and suggested that the soft valve ring may help prevent biological valve failure, which is widely applied at home and abroad.

In 1999, regrading the Chinese coagulation/anti-coagulation predisposition, the Center first put forward the strategy of low-intensity anti-anticoagulation (INR1.7-2.0) after the mechanic valve replacement operation, which reduced the postoperation complications significantly. A series of innovative concepts were advanced in the research and development of heart valve pathology and valve replacement. More than 4o SCI papers were published and 2 national invention patents acquired, in addition, the number of heart transplantation operation ranked first in China for consecutive 4 years (2014, 2015, 2016, 2017), by which valuable biological samples were provided for clinical and basic research.

D. Achievement, Awards, Publications

The team was early pioneers and advocates of innovative concepts like “composite stent”, “improvement of biological properties by activated molecular”, “stent cross-link modification to improve mechanical properties” and “micro-environment simulation” etc. A new type of tissue engineering heart valve was successfully invented and 2 national patents acquired. The team has completed one national projects supported by the Ministry of Science and Technology, one national “863” project, and 6 projects founded by national natural science foundation with one key project. In 2016, Prof. DONG Nianguo was appointed as chief coordinator to take in charge of "National Key Research & Development Plan - Stem Cell and Transformation Research", supported by the Ministry of Science and Technology (Project No.: 2016YFA0101100, the Construction of Heart Valves Based on the Autologous Stem Cell, funds 28,92million).

Eight major achievements have been awarded by the Ministry of Education, the Ministry of Health and the Chinese Medical Association etc. Four first prizes known as Hubei Provincial Scientific and Technological Progress was awarded. The teams has edited the national textbook Surgery (the 8th edition) for Chinese medical undergraduates and compiled 5 medical monographs named as "Aorta Surgery", "Cardiovascular Disease Immunology", "Cardiovascular Surgery Today" etc., and published 200+ papers, including 60+ SCI.

 

 


Prof. WU Gang’s Team

----Thoracic Radiation & Oncology

 

A. Introduction of the team

The Department of Thoracic Radiation and Medical Oncology (DTRMO) was one of the most important department in Cancer Center, Union Hospital. The department is now a recognized regional leading unit in providing expert, prompt cancer care, high quality teaching and research in the field of thoracic cancer chemotherapy and radiotherapy. It was initially founded in 2007 and by the year 2012, a subspecialty ward of thoracic oncology has been established. There are 208 beds and 24 physicians, including 3 professors, 5 associate professors, 12 out of the 24 physicians having oversea experiences in Europe and USA.

 

Academic Leader: Professor Dr. Wu Gang, Chief physician, Second grade professor, Doctor Supervisor, Director of the Cancer Center, research interests: Precision radiotherapy and tumor microenvironment of lung cancer

Prof. WU is the Vice Chairman of the Radiation Oncology branch of China Science and Technology Industry Association, standing committee member of the Chinese Society of Radiation Oncology and the Radiation Oncologist Branch of Chinese Medical Doctor Association, member of the Anit-cancer Drug Division of Chinese Pharmaceutical Association etc. deputy editor in chief of “Radiation Oncology, and published 140+ papers, including 70+ SCI papers, with the highest SCI IF 13.2.

Primary members of the academic team:

Name

Title/age

Research directions

No. of NSFC Foundation/Key Programs Chaired

Oversea experience /SCI papers

Liu Li

Prof./57

Immunotherapy for lung cancer

3/1

Germany/20

Dong Xiaorong

Prof./42

Radiobiology of lung cancer

4

Germany/20

Zhang Sheng

Associate chief physician/43

Precision radiotherapy for lung cancer

1

Germany/10

Xu Shuangbing

 

Associate professor /36

Radiobiology of lung cancer

2

USA/13

Meng Rui

Attending physician/37

 

Molecular targeted therapy for  lung cancer

1

Germany/13

Key members of the academic team

Name

Title/age

Research directions

No. of NSFC Foundation/Key Programs Chaired

/SCI

Oversea experience /SCI papers

Dai Xiaofang

Associate chief physician/49

Precision radiotherapy for lung cancer

1

USA/5

Liu Jun

Associate professor /37

Molecular targeted therapy for  lung cancer

2

USA/6

Yin Zhongyuan

Associate chief physician/39

CT guided biopsy for lung cancer


None/6

Jin Honglin

Research Assistant

/36

Diagnosis of lung cancer by molecular typing

1

Canada/30

Zhang Ruiguang

 

Attending physician/35

Precision radiotherapy for lung cancer

1

USA/6

Liu Pian

Attending physician/33

Molecular targeted therapy for  lung cancer

2

USA/8

Li Zhenyu

Attending physician/36

Radiobiology of lung cancer

1

USA/7

Hong Xiaohua

Attending physician/33

Precision radiotherapy for lung cancer

1

USA/5

B. Research Directions

1. Precise radiotherapy for lung cancer: precise radiotherapy based on imaging omics, precise radiotherapy based on genomics

2. Precise target of tumor microenvironment in lung cancer

1) Radibiology: study on the molecular mechanism of radioresistance of lung cancer cells, study on the molecular mechanism of radiation-induced injury of brain(RIB).

2) Antiangiogenic and immunotherapy of lung cancer: lead clinical trials of evaluating the safty and efficacy of vesicle therapy in malignant pleural effeusion in lung cancer, study on the molecular mechanism of antiangiogenic therapy in lung cancer.

3) Study on the molecular mechanism of immunotherapy in lung cancer.

3. Precise molecular targeted therapy for lung cancer

C. Achievement

Over the past 10 years, the team has chaired chaired one 2016 key project of the Ministry of Science and Technology Development and evaluation of digital medical equipment (12 million), 25 projects from NSFC and 8 provincial projects; 1 Sub-project under the Special Subjects of Chronic Disease of National Health and Family Planning Commission (2.3 million). In addition, there are over 70 SCI papers published by the team and actively edited  textbooks planned by the national "11th Five-Year" and "13th Five-Year" programme.

 

 


Prof. SHAO Zengwu’s Team

---- Bone Orthopaedics & Spine, Pelvic, Limb Tumors

 

A. Introduction of the Team

Academic Leader: Prof. SHAO Zengwu: Ph.D awarded at Germany; National second-level professor, chief physician, doctoral supervisor, chief scientist of National Key Research and Development Program, honorary professor of SWANSEA University of USA, chairman of the Subcommittee for Spine Repair Material and Technology of Chinese Society for Biomaterials, vice chairman of the Department of Bone Tumors of SICOT China, vice chairman of the Bone Tumor Working Committee of China's Integration of Chinese and Western Medicine Committee Orthopaedic Injury Society. Prof. Shao was awarded 2 provincial second prizes of scientific and technological progress, one second-class scientific and technological progress award of Wuhan and 2013 Zhao Yisu Orthopaedic Basic Research Award and Chinese Overseas Fifth Innovation Achievement Award.

Team Members

Prof. Guo Xiaodong: Postdoctor of University of Toronto, Canada, doctoral supervisor of Department of Orthopaedic Surgery of Affiliated Union Hospital, a winner of Education Ministry's New Century Excellent Talents Supporting Plan and an outstanding young scholar of Osteoporosis and Bone Mineral Disease Clinical Research of Chinese Medical Association. He received six projects funded by the National Natural Science Foundation projects, one from the Special Foundation for International Science and Technology Cooperation in China/Canada, one from "New Century Excellent Talent Support Plan" of ministry of education, published 162 papers including 50+ SCI papers.

Prof. ZHANG Keqin: The "Thousand Talents Program" expert of Central Organization DepartmentDistinguished Professor of Suzhou University, doctoral supervisor, published 50 academic papers in the top SCI journals, one of which in "Nature" and 3 monographs. He has applied for 20+ patents, in which 10 authorized, hosted 3 National Natural Science Foundation projects and 3 science and technology innovation teams of Jiangsu province and other provincial and ministerial projects.

Prof. ZHANG Zhiyong : full professor, doctoral supervisor. He is responsible for the establishment of Research Center of Regenerative Medicine and 3D Printing Technology Transformation of Guangzhou Medical University and serves as the center director. He was selected into the "Thousand Talents Program of Youth" and won 13 international and domestic academic awards, including the first prize of Natural Science of Ministry of Education and the second prize of the Chinese Medical Science and Technology Award; published 20+ SCI papers.

Prof. CAO Yang: Deputy Director of Orthopaedic department, chief physician, doctor of medicine, doctoral supervisor, postdoctor of Harvard University, member of Ministry of Education New Century Outstanding Talents Support Program. He served as the youth member of the Chinese Medical Association Orthopaedic Society, Member of Minimally Invasive Group of Chinese Medical Association Orthopaedic Society and other multiple duties; coordinator of 4 National Natural Science Foundation projects and 11 other national or provincial level projects including the new century excellent talent program of the ministry of education.

Prof. LIU Guohui: Deputy Director of Orthopaedic department, chief physician, doctor of medicine. He served as a permanent member of Chinese Trauma Committee of Societe Internationale de Chirurgie Orthopedique et de Traumatologie (SICOT), permanent member of Trauma Specialized Committee of Department of Orthopaedic of Medical Doctor Association, National Committee of Traumatology Society of the Chinese Medical Association; coordinator of 3 projects funded by the National Natural Science Foundation. He won the third prize of Science and Technology Innovation of Hubei Province; published 170+ papers in the first-class journals at home and abroad, in which 10+ papers indexed by SCI.

Prof. XIONG Liming: Associate professor, master's supervisor, associate chief physician. He has hosted 2 National Natural Science Foundation projects, 3 provincial and municipal projects. He has published 35 papers, in which 6 papers were indexed by SCI. His research on intervertebral disc degeneration won the second prize of Hubei Science and Technology Progress Award, the second prize of Wuhan science and technology progress award and got one practical and new patent.

Prof. ZHANG Yukun, master supervisor, associate chief physician, evaluation expert of the National Natural Science Foundation. In 2013, he was a visiting scholar at the Wharton Center in Liverpool, England. He hosted 3 projects funded by the National Science Foundation of China and published 15 SCI papers.

Prof. FENG Yong: Associate professor, associate chief physician, master's supervisor, postdoctor of Harvard University. He has hosted 2 projects funded by the National Natural Science Foundation and won the first prize of Hubei science and technology promotion award. He has published more than 10 papers in important international journals.

 

Research Direction

1. Organ aging and degeneration of the skeletal system.

2. Basic and clinical research of malignant bone tumor.

Advantages and Resources

The team boasts the Bone Diseases Institution, 3D Digital Orthopaedic R&D Center and the center of genetic diagnosis and clinical translation of Union Hospital, National Engineering Laboratory for Modern Silk of Soochow University, Research center for regenerative medicine and 3D printing transformation of Guangzhou Medical University.

 

 

 


Prof. HUANG Kai’s Team

---- Metabolic Disorders

 

A. Introduction of the Team

Academic Leader: Prof. Dr. HUANG Kai, vice-dean of Union Hospital, Yangtze River Scholar, chief physician of cardiovascular medicine.

Prof. Dr Huang acquired his Ph.D degree in 1999 and pursued postdoctoral research in cardiac electrophysiology and molecular biology at Columbia University and University of California San Francisco in U.S.A, funded for decades by Science and Technology Ministry of China, Ministry of Education of China, NSFC and Hubei Provincial Government. Being the fellowship of American College of Cardiology, he also serves as the chairman or board member of the Chinese Society of Cardiovascular Diseases, the Chinese Medical Doctor Association branch of cardiovascular disease, the Chinese Medical Doctor Association Council etc. Prof. HUANG won high reputation in cardiovascular diseases field for his abundant publications on top tier international journals, and serves as editor-in-chief and honorable reviewer of many authoritative journals in the field.

Primary team members:

Study Field

Name

Title

lipid metabolism disorders and vascular remodeling

HUANG Dan

Associate Professor

CHENG Min

Associate Professor

ZHU Feng

Associate professor

HE Shaolin

Resident

WANG Cheng

Resident

LIANG Minlu

Technician

diabetic heart diseases and micro-vascular lesion

FU Qin

Associate Professor

WANG Yan

Associate Professor

LUO Xi

Resident

HU Lizhi

Technician

CHEN Long

Technician

non-alcoholic fatty liver

YANG Ling

Professor

HUANG Kun

Resident

ZHANG Fengxiao

Resident

PENG Jiangtong

Resident

DU Meng

Resident

LI Xiaoguang

Technician

B. Research Direction

The basic research and clinical treatment on the pathogenesis of metabolic disorders and cardiovascular diseases

1. Multiple research on diseases associated with lipid metabolism and vascular remodeling, the feasible prevention and treatment strategy on this basis.

2. The pathogenesis and intervention of diabetic heart disease and micro-vascular lesion.

3. The pathogenesis of non-alcoholic fatty liver and its effects and mechanism of action on cardiovascular system

C. Advantages and Resources

Department of Cardiology of Union Hospital, is the national key subjects of the Ministry of Education, National Key Clinical Specialties of the Ministry of Public Health of China. This department is composed of cardiovascular disease clinical center (including cardiovascular medicine and surgery, cardiovascular interventional diagnosis and treatment and cardiovascular molecular imaging center), cardiovascular basic research center, human genome clinical research center and collaborative product innovation platform of new drug research and application for cardiovascular and metabolic diseases. The platform has a total laboratory of 4000 square meters, 50 large-scale instruments and equipment worth 100 thousand yuan and the total value approximately 70 billion yuan. Experimental instruments include liquid chromatography mass spectrometry/mass spectrometry (LC-MS/MS), isolated vascular perfusion and functional detection system, ultrasonic apparatus for live animals, biologic duoflow protein chromatography system, laser scanning confocal microscope, electron microscope, flow cytometer, heraeus sepatech, electrophoresis apparatus, gel documentation system, frozen and ordinary microtome, pathological test imaging system, laboratory animal center with specific pathogen free(SPF) level and other advanced instruments. Aiming at the international subject frontiers and combining the pathological characteristics of cardiovascular disease, this team is absorbed to resolve major clinical and scientific issues facing in the cardiovascular disease research and formed the disciplinary characteristic in cardiovascular disease metabonomics, cardiovascular disease immunology and molecular cardiology study guided with the mechanism of coronary cardiac disease. In the field of cardiac transplant, team’s clinical medicine and scientific research is in the front rank in the whole country. The team has also obtained a series of high-level and influential achievements in cardiovascular molecular imaging research, especially in the cardiac nuclide imaging and ultrasonic contrast. The major clinical and basic research of this team includes cardiovascular and metabolic diseases, cardiovascular disease immunology, cardiac electrophysiology, cardiac molecular biology, interventional cardiology and cardiac failure.  

D. Achievement & Awards

The team has long been engaged in the research on the clinical treatment of cardiovascular diseases and metabolic syndromes, and attained a series of innovative achievements: It discovered the new pathogenesis of cardiovascular and metabolic diseases, such as acute coronary artery syndrome (ACS), blood hypertension, heart failure etc, which provides a solid theoretical foundation and experimental gist for the progress of clinical treatment of those diseases. The research team has published 50+ highly influential papers in science journals like Journal of Hepatology, Am J Pathol, PNAS, J Am Col Cardio, PloS genetics, Hepatology, Oncogene, J Biol Chem, Circulation, Circ Res, Am J Path etc.

 

 

 


Prof. CHEN Xiaoping’s Team

----Hepatopancreatobiliary Surgery

 

A. Introduction of the Team

Academic Leader: Prof. Dr. CHEN Xiaoping, academician of Chinese Academy of Science, chairman of Department of Surgery Director of the Institute of Hepato-pancreato-biliary Surgery and Hepatic Surgery Center of Tongji Hospital.

Prof. CHEN obtained his M.D. in 1985 and then got further trained in Germany and United States, dedicated to hepatopancreatobiliary surgery for 40+ years, and established a number of innovative techniques for HPB surgery and did significant contribution to academic society, especially A-PHPBA. He received the International Scholar title from the American Cleveland Medical Communication Center, earned American Sackler Chinese Doctor Annual Award in 1996, received WU Meng-chao Hepatobiliary Surgery Foundation Award in 1997. In 2002, his studies on“Series of Research & Technique Amelioration in Hepatic Surgery”made him the first winner of the Chinese Medical Association Award. He was elected Director of the Hepatic Surgery Group of Chinese Medical Association in 2002, and president of the Chinese Chapter of the International Hepato-pancreato-biliary Association in 2003. His “The Research on Basic & Clinical Application in Hepatic Surgical Operation” won the National Science and Technology Progress Award in 2004.

   Prof. Dr. Chen has been performing clinical practice focusing on HBP surgery characterized by a broad spectrum of malignant carcinoma associated with liver, bile duct and pancreas. He also dedicates himself to clinical liver transplantation. In addition to clinical practice and administrative obligations, Prof. Dr. Chen is an unrelenting researcher and pioneer in the field of cancer biology and clinical trials. He has published 500+ peer-reviewed articles and won funding from the NSFC (Natural Science Foundation of China) for decades. He possesses the title of editor-in-chief and honorable reviewer of more than 30 domestic and international journals.

Main Team Members

Prof. Dr. ZHANG Bixiang, post-doctor in Vanderbilt University in U.S.A. in 2006-2009, specialist in molecular mechanism research and targeting intervention treatment on tumor organ-specific metastasis, expert surgeon in performing highly difficult HPB surgeries like hepatectomy, hilar cholangiocarcinoma, pancreaticoduodenectomy, cholelithiasis and liver transplantation. He has sponsored 4 General Programs of NSFC (Natural Science Foundation of China) and participated in many key programs of NSFC, MOHC (Ministry of Health of the People's Republic of China) and so on, with publication of 60+ SCI papers.

Prof. ZHANG Zhiwei, specialist in liver regeneration, did basic and clinical research on liver transplantation and hepatogenesis in Hong Kong University in 1999-2000. He participated in one “973 Program”, one national “10th Five-Year Plan” project, 2 NSFC projects, 4 Provincial and Ministry Projects, and published 70+ papers.

Prof. HUANG Zhiyong, deputy director of the Discipline Construction Office and the General Surgical Research Laboratory of Tongji Hospital, member of the Education and Training Committee of the International Hepato-Pancreato-Biliary Association (IHPBA) (2014-2018), standing committee member of the Asian-Pacific Hepato Pancreatic Biliary Association (APHPBA) (2015-2017), member of the APHPBA Research Committee (2011-2015) and the Secretary General of the IHPBA China Chapter (2004-).

Prof. CHEN Yifa, doctoral student of Prof. QIU Fazu, engaged in clinical surgical treatment for 20+ years, rich clinical experience in all kinds of hpb and splenic diseases, especially the diagnosis and surgical treatment of different benign and malignant liver and gallbladder tumors, portal hypertension and malignant obstructive jaundice. Prof. Chen has compiled or participated in writing 10 surgery medical monographs in the field.

B. Main Research Areas:

hepatopancreatobiliary surgery: treatment and resection of hepatocellular carcinoma ; hemostasis in liver surgery; assisted partial liver transplantation; small-range hepatectomy in hilar cholangiocarcinoma; invaginated pancreaticojejunostomy. Research on the molecular mechanism of recurrence and metastasis of liver cancer.

C. Background & Significance

1. Research Background

Pancreatohepatobiliary diseases impose serious hazards to people's health. Among them, liver cancer is one of the most common malignant tumors in China, 50% of the world's liver cancer patients are in mainland China, which top the world in new morbidity and mortality. At present, the incidence of hepatocellular carcinoma in China is about 25.7/100,000, which is the third largest malignancy after gastric and lung cancer. Though combined treatment with surgical resection is recognized to be the best treatment, how to reduce surgical bleeding, complications and mortality, and improve long-term survival is a key challenge in this field. At the same time, liver transplantation is the most effective way to treat various liver metabolism malfunction, fulminant hepatic failure and advanced schistosomiasis patients. However, due to the shortage of donors, how to improve the long-term survival of graft needs to be studied with comprehensive perspectives concerning anatomy, hemodynamics, oncology, pathology and operative surgery etc.

Primary hepatocellular carcinomas has rather poor prognosis due to recurrence and metastasis after surgical resection, which needs further studies to provide theoretical basis for locating accurate tumor markers and developing new target therapy drugs. Progress of treatment and concepts innovation are constantly needed to improve the prognosis.

2. Academic Strength

Liver Surgery Department of Tongji Hospital of HUST, one of the largest diagnosis and treatment center for liver cancer whose comprehensive strength tops the world, enjoys high domestic and international reputation. There are 218 beds in the center which admits 4,000+ inward patients and performs 2,000+ surgical operations annually. Liver minimally invasive treatment wards and postoperative wards are established earliest in China. A multidisciplinary diagnosis and treatment team of liver cancer, including surgery, oncology, ultrasound, imaging, gastroenterology, infection and pathology has been established and perfected. The Department has 3-dimension liver reconstruction system, indocyanine green liver reserve function analysis system, Da Vinci surgical robot, high-definition 3D laparoscopy, bipolar electric coagulation forceps, ultrasonic scalpel, CUSA, intraoperative ultrasound, navigation equipment etc. Professional perioperative data collection, biological sample collection and postoperative follow-up team were established. It has also formed laboratory engaged in basic research on liver invasion and metastasis of malignant tumor, equipped with cell culture apparatus, high-speed centrifuge at low temperature, fluorescence quantitative PCR, gel imaging system, laser confocal microscopy, immune enzyme-linked analysis, double fluorescent reporter gene detection system etc.

D. Achievement & Awards

1. The earliest liver resection to treat hepatoma in China (in 1958) and the earliest clinical trial in liver transplantation (in 1980), awarded the First Prize of Science and Technology Progress by Ministry of Health;

2.     Earliest advocate of the feasibility to treat large-size hepatoma by hepatectomy and established a series of innovative surgical techniques, awarded the Second Prize of National Science and Technology Progress;  

3. The coordinator for CMA(China Medical Association) to formulate the Options for Surgery to Treat primary Hepatoma and the Diagram of Diagnosis and Treatment for Hepatocellular carcinoma;

4. Coordinator to formulate the Operating Regulation in Minimally Invasive Treatment of Hepatocellular Carcinoma in China;

5. Initiator and promoter of laparoscopy to perform hepatectomy in China and Asian-Pacific Region;

6. The number and difficulty of liver resection by robot top the world leading level;

7. The initiator of in situ assisted partial liver transplantation model and apply it to clinical practice in the world;

8. First performer of small-range hepatectomy and biliary-enteric anastomosis surgery to treat hilar cholangiocarcinoma;

9. First performer of the surgery described as invaginated pancreaticojejunostomy with transpancreatic U-sutures;

10. A series of research findings in the molecular mechanism of recurrence and metastasis of liver cancer.

 

 


Prof. MA Ding’s Team

---- Gynecological Oncology

 

A. Introduction of the Team:

After many years of construction, the team has a rational academic echelon, with 90% of its members holding Ph.D., and most of the academic elites have studied or studied abroad.  Through optimized combination and innovation, the team has been awarded the title of “innovation team of the Ministry of Education” in 2008. With the improvement of the laboratory hardware facilities, 18 million yuan has been invested in the construction of laboratory in the nearly past five years, of which 16 million yuan for the acquisition of laboratory equipment. Gynecologic Oncology Laboratory was approved as "Key Laboratory of Tumor Invasion and Metastasis in Hubei Province" in 2007 and passed the acceptance test by the Ministry of Education in 2013. It has won the "Key Laboratory of Tumor Invasion and Migration" issued by the Ministry of Education.

Academic leader: Prof. Dr. Ding Ma, newly-elected academician of Chinese Academy of Engineering, Chairmen of Department Obstetrics and Gynecology of Tongji Hospital, who has engaged in clinical practice and research for 30+ years and grown into a top specialist in diagnosis and treatment of gynecological tumors and gynecological diseases. He performed more than 10,000 operations with remarkable expertise in gynecological, minimally invasive and robotic surgery. Meanwhile, he has made outstanding contribution to preventing malignant neoplasms and containment of tumor metastasis: 1) unique achievements in improving treatment strategy of cervical cancer patients by combining systematic neoadjuvant chemotherapy and improved operative techniques to preserve female genital organs and functions. 2) first uncovered the susceptibility loci for cervical cancer and human papillomavirus (HPV) integration site. His team built an early alert model and new strategy of prevention and treatment of cervical cancer, in the aim to effectively improving the level of our national clinical care for cervical cancer. 3) first identified a short synthetic peptides targeting and eliminating the micrometastatic loci in the world. He insisted on transferring results from basic researches into the clinical applications. TMTP1, a labeled targeting peptide has been used in clinical diagnosis. “Adenovirus Thymidine Kinase (ADV-TK) Gene Therapy”, an innovative drug, has been completed successfully, then entering phase III clinical trial.

Team Members:

Prof. WANG Shixuan, PhD supervisor, deputy director of the Department of Obstetricians and Gynecologists and the director of Gynecology Department at the Union Hospital; the deputy director of the Chinese National Center for Obstetrics and Gynecology and the Key Laboratory for Invasion and Metastasis of Tumor funded and administered by the Chinese Education Ministry and Hubei Provincial Government.

Prof. WANG Hui, Changjiang Scholars and Distinguished Professor of the Chinese Education Ministry, PhD supervisor, post-doctoral fellow of the University of Pittsburgh Medical Center and Zhejiang University in cancer research. Prof. WANG has won 4 National Natural Science Fund Projects and one research project of the “973-Program”, with primary research involves screening of the pathogenesis and precancerous lesions of cervical cancer. In recent 5 years he has published 24 research papers in SCI-Journals like Nature Genetics, J Clin Invest and Cancer Res. In 2014 he won the 1st prize of Award for Scientific and Technological Progress in Hubei Province.

Prof. GAO Qinglei, Professor, PhD supervisor, American post-doctoral fellow. She is also the winner of 4 National Natural Science Funds, one of the academic experts from the Expert Database of the Chinese National Precision Medicine. Her doctoral thesis was nominated as the “Chinese National Best 100 Doctoral Theses”. She has published 100 papers, among which 50 papers are SCI-Journal articles, both at home and abroad.

Prof. CHEN Gang, the deputy director of the Clinic for Gynecological Oncology, 20+ years working experience. As PI of the Key Laboratory for Invasion and Metastasis of Tumor funded and administered by the Chinese Education Ministry and the government of Hubei Province, Prof. CHEN focuses on the research of carcinogenesis and metastasis, molecular mechanisms of drug-resistance and clinical Translation of ovarian carcinoma. In recent 5 years he published 20+ papers in SCI-Journals like JNCIOncotarget and so on.

Prof. WU Peng, deputy director of the Clinic for Gynecological Oncology. From July 2014 to October 2017 he worked at the Center for Microbiology, Immunology and Cancer of the University of Virginia Medical School as visiting scholar. Back at home his major research focuses on the persistent infection of HPV in the pathogenic mechanism of cervical cancer. In recent 5 years he published about 10 papers in SCI-Journals like Cell Death & differentiation and Cell death &disease and won 4 major awards at the national and the ministerial or provincial level. Besides, he’s also the reviewer or editor of Science Journals like Oncotarget, Scientific Report, Tumor biology, Gynecologic Oncology and so on.

B. Main research areas

    Mechanism of tumor metastasis and targeted therapy, the pathogenesis of high-risk HPV-induced cervical cancer and its precancerous lesions screening, early intervention of cervical cancer and ovarian cancer’s molecular typing.

C. Background and Significance

    According to "National Medium and Long-term Scientific and Technological Development Plan (2006-2020)", “population and health” has been determined to be the key field nationally. Gynecologic and obstetric diseases are deeply intertwined with the national economy, the people's livelihood and even the key issue of the quality of the population. In view of a lack of a standardized and sound diagnosis & treatment system and early warning & intervention mechanisms in the field of gynecologic and obstetric diseases in our country, meeting the ever-increasing and urgent clinical needs has become an important direction for the development of this field in the new century.

The comprehensive strength of the team ranks the top 3 among many similar institutions for many years and our team is one of the most influential academic team in China due to a series of landmark achievements below: ① in cervical cancer research, the secret of Han Chinese women cervical cancer’s gene codes has been disclosed for the first time as a result of the discovery of its susceptibility loci and HPV integration sites, and many articles about it were published in Nature Genetics by the first author or Corresponding author. Simultaneously, a new integration site of cervical cancer was identified and genetic editing tools were used to reverse persistent HPV infection and precancerous lesions successfully based on the previous findings. Relevant research results were published in Nature Genetics, JCI et al. International authoritative journals, the use of zinc finger ribozyme vaginal suppository has passed the hospital ethical approval, and we also successfully registered it for international clinical trials, and it has achieved good clinical efficacy in patients with cervical precancerous lesions. ②in the field of ovarian cancer, an ultrasound image recognition system was developed for ovarian cancer with artificial intelligence recognition and reaped fruitful results in the early diagnosis and immunotherapy of ovarian cancer. ③ in the area of tumor metastasis, the team synthesized the first specific targeted peptide which can recognize and eradicate the micro-metastasis, which won 7 national invention patents and with China's independent intellectual property rights, anticancer drug "recombinant adenovirus - thymidine kinase gene preparation" has proceeded into the phase III clinical trials. ④ resort to "invasion and metastasis of the Ministry of Education Key Laboratory" of Obstetrics and Gynecology Department, the team has become one of the most prominent supporting strengths in this discipline.

D. Major Scientific Findings

1. Biological characteristics of cervical cancer research and establishment & application of early prevention & treatment of cervical cancer 2010 (second prize of national science and technology progress prize).

2. The mechanisms of the progression of ovarian cancer and the research & application of its repression strategies 2011 (second prize of national science and technology progress prize).

3. The application of molecular target therapy of tumor metastasis 2012 (second prize of national science and technology progress prize).

4. New features of cervical cancer and the application of the new strategies of clinical diagnosis & treatment 2014 (first prize of Hubei Science and Technology Progress Award).

E. Achievement and Awards

In the recent five years, the team of gynecologic oncology led by Professor Ma has been responsible for 1 project (chief unit) of 973 National Projects, 2 projects of National 863 Projects, and 30+ million funded by NSFC, 2 projects of the National Outstanding Youth Funds and 2 projects of Overseas Youth Cooperation (Outstanding Youth Fund B), 15 projects of National NSFC and 39 provincial or ministerial projects. 739 papers and 18 monographs were published in domestic and foreign core journals. 5. long-term close academic collaboration with United States Texas Southwestern Medical Center, MD Anderson Cancer Center, New York Cornell University, University of Pennsylvania School of Medicine Philadelphia Children's Hospital Department of Pathology and Laboratory Medicine, Germany Essen University, University of Oxford and Switzerland Basel University etc.

 

 

 


Prof. WANG Wei’s Team

----Functional Glia-Neuron Coupling & Ischemic Neuro-Protection

 

A. Introduction of the Team

The team includes 1 Chinese Academician of Science, 2 national distinguished young scientists, 1 Changjiang Scholar, 2 chief scientists of 973 project.

Academic Leader: Prof. Dr. WANG Wei, the Dean of Tongji Hospital, Head of the Neurology Department.

Prof. WANG Wei acquired his master Degree in medicine in The Third Military Medical University and Ph.D. in Chongqing Medical University, a visiting scholar in the Dept. of Neurology University of Heirich-Heine, Germany where he acquired his second Ph.D. Prof. WANG was awarded the Excellent Young Scientist Fellowship in 2004 and Changjiang Scholarship in 2009 by Ministry of Education. In 2017, he won the National Natural Science Award from the State Council of the People's Republic of China. He was the editor-in-chief of “Nature Review Neurology, and “Journal of Neuronal Damage and Functional Reconstruction”, deputy director of Society for Neuroscience of China and Associate director of Medical Society of China.

Team Members: Prof. XIE Minjie; Prof. ZHANG Min; Prof. YU Zhiyuan; Prof. TIAN Daishi; Prof. WANG Minhuan; Prof. ZHANG Qiang; Dr. DING Fengfei ;

B. Main Research Areas

Functional glia-neuron coupling and ischemic neuroprotection

C. Background & Significance

Stroke is a leading cause for mortality and disability in China and around the world. Past research and neurotherapeutic clinical trials have targeted the molecular mechanisms of neuronal cell death during stroke, but all failed and the underlying pathogenesis remains unknown. Recent research suggests brain function and dysfunction are manifested at the level of cell–cell signaling between neuronal, glial and vascular (neurovascular unit) elements. The team focuses on studying the neurovascular unit signaling and functional coupling during normal and ischemic conditions, and tries to determine the response and function of glia which plays an active role in ischemic pathology under stroke and depression conditions.

1.first found that glial cells regulate nerve activity and cell migrationvia releasing ATP by lysosomes and promoting Ca2 + diffusion wave. The team provides the first in vivo evidence showing the impairment of working memory by cannabinoids due to the activation of astroglial CB1R associated with astroglia-dependent hippocampal LTD in vivo and revealed novel mechanistic views of the role of astrocytes in learning and memory processes.

2. identified that ischemia induced gliosis and glia scar formation determine the micro environment for neuronal damage and repair. Regulation of the cell cycle can reduce neuronal apoptosis and glial scar formation. Suppressing the cell cycle by specific inhibitors may constitute potential therapeutic methods in neurological disorders including ischemic stroke.
   3. revealed the gap junctional coupling properties between astrocytes under normal and ischemic conditions. Astroglial GJC plays a significant role in MCAO-induced remote hippocampal damage and cognitive impairment, which suggests manipulating GJC could be a new target in protecting stroke patients

D. Achievement, Awards, Publications

The team has published 125 papers, among which 8 published in Cell, Nature cell biology, Ann Neurol, Prog Neurobiology and other top international journals, with a total impact factor of 99.215. Key findings are highlighted and reviewed in Nature Rev Neurosci, Nature Neurosci etc, which were cited multiple times in Nature Reviews, Molecular Cell Biology, Lancet, JAMA etc. (IF> 20 papers cited 24 times; IF > 10 papers cited 50 times). Part of the researchings have been written in textbook for medical students. The findings were reported by 150+ international media including BBC, Nature, Science. The team hosted 3 major international conferences; 20 special reports were delivered at the International Conferences, with Prof. WANG being President 8 times.

Address: No.13, Hangkong Road, Wuhan, Hubei, P.R. China; zip code:430030